PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT6907104

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
AERPIO PHARMACEUTICALS, INC.	08/26/2021

RECEIVING PARTY DATA

Name:	EYEPOINT PHARMACEUTICALS, INC.
Street Address:	480 PLEASANT STREET, SUITE A-210
City:	WATERTOWN
State/Country:	MASSACHUSETTS
Postal Code:	02472

PROPERTY NUMBERS Total: 133

Property Type	Number
Application Number:	60816730
Application Number:	60816731
Application Number:	60816825
Patent Number:	7622593
Patent Number:	7795444
Patent Number:	7589212
Patent Number:	8258311
Patent Number:	8338615
Patent Number:	8946232
Patent Number:	8895563
Patent Number:	8329916
Patent Number:	9126958
Patent Number:	9284285
Patent Number:	9795594
Patent Number:	10463650
Application Number:	16577808
Application Number:	17096548
Application Number:	12558169
Patent Number:	8106078
Patent Number:	8188125

PATENT REEL: 057448 FRAME: 0033

506860284

Property Type	Number
Application Number:	13626590
Patent Number:	8846685
Patent Number:	RE46592
Application Number:	61144022
Application Number:	61184986
Application Number:	14075809
Application Number:	15443353
Application Number:	16719317
Application Number:	15930583
Application Number:	13968269
Patent Number:	9096555
Application Number:	12677512
Application Number:	61223260
Patent Number:	8883832
Patent Number:	9174950
Patent Number:	9949956
Application Number:	15913392
Application Number:	16582619
Application Number:	61390899
Application Number:	13253397
Application Number:	14300385
Application Number:	15462326
Application Number:	16513103
Application Number:	17352698
Application Number:	15796293
Application Number:	61792679
Application Number:	61792868
Application Number:	61882048
Application Number:	61882056
Application Number:	61934570
Patent Number:	9440963
Application Number:	14214413
Application Number:	15098955
Application Number:	15099161
Patent Number:	10220048
Application Number:	15443622
Application Number:	15958346
Application Number:	15958355

Property Type	Number
Application Number:	15958358
Application Number:	15969109
Application Number:	16257287
Application Number:	16559006
Application Number:	16888247
Application Number:	17155463
Application Number:	61953680
Patent Number:	9994560
Patent Number:	10858354
Application Number:	17062098
Application Number:	62019002
Application Number:	62190871
Application Number:	62361703
Application Number:	62222481
Patent Number:	10952992
Application Number:	17150430
Application Number:	62635102
Application Number:	62790646
Application Number:	16284349
Application Number:	17130687
Application Number:	62835626
Application Number:	62840655
Application Number:	16850613
Application Number:	62865653
Application Number:	63009083
Application Number:	16908996
Application Number:	62927233
Application Number:	17082612
Application Number:	62840068
Application Number:	16860347
Application Number:	62958348
Application Number:	63089144
Application Number:	17143394
Application Number:	63127412
Application Number:	63127411
Application Number:	63028317
Application Number:	60790506
Application Number:	60798896

Property Type	Number
Patent Number:	7973142
Patent Number:	9926367
Application Number:	15894442
Application Number:	16696212
Application Number:	16784970
Patent Number:	8524235
Application Number:	13958990
Application Number:	61546708
Patent Number:	8999325
Application Number:	14627463
Patent Number:	10329357
Application Number:	16395972
Application Number:	16751824
Application Number:	61546697
Application Number:	61546748
Application Number:	13652203
Patent Number:	10150811
Patent Number:	10815300
Application Number:	17027034
Application Number:	62054752
Application Number:	14862948
Application Number:	15815097
Application Number:	62364381
Application Number:	62377072
Patent Number:	10253094
Patent Number:	10604569
Patent Number:	10597452
Application Number:	16775860
Application Number:	16851420
Application Number:	62735331
Application Number:	62832461
Patent Number:	10894824
Application Number:	17117993
Patent Number:	8569348
Application Number:	62034695
Patent Number:	9539245
Application Number:	15365186

CORRESPONDENCE DATA

Fax Number: (650)493-6811

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email:patentdocket@wsgr.com, rgallo@wsgr.comCorrespondent Name:WILSON SONSINI GOODRICH & ROSATI

Address Line 1: 650 PAGE MILL ROAD

Address Line 4: PALO ALTO, CALIFORNIA 94304-1050

ATTORNEY DOCKET NUMBER:	61881
NAME OF SUBMITTER:	CARMEN CHOW
SIGNATURE:	/Carmen Chow/
DATE SIGNED:	09/09/2021

Total Attachments: 60

source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page1.tif source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page2.tif source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page3.tif source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page4.tif source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page5.tif source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page6.tif source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page7.tif source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page8.tif source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page9.tif source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page10.tif source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page11.tif source=EvePoint 61881-Aerpio - Patent Assignment EXECUTED#page12.tif source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page13.tif source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page14.tif source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page15.tif source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page16.tif source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page17.tif source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page18.tif source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page19.tif source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page20.tif source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page21.tif source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page22.tif source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page23.tif source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page24.tif source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page25.tif source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page26.tif source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page27.tif source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page28.tif source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page29.tif source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page30.tif source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page31.tif source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page32.tif source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page33.tif

source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page34.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page35.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page36.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page37.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page38.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page39.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page40.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page41.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page42.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page43.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page44.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page45.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page46.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page47.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page48.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page49.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page50.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page51.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page52.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page53.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page54.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page55.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page56.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page57.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page58.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page59.tif
source=EyePoint 61881-Aerpio - Patent Assignment EXECUTED#page60.tif

EXHIBIT D

PATENT ASSIGNMENT

CORPORATE TO CORPORATE PATENT ASSIGNMENT

Docket Number 45725-700

Aerpio Pharmaceuticals, Inc., a corporation of the State of <u>Delaware</u>, having a place of business at <u>9987 Carver Road</u>, <u>Suite 420</u>, <u>Cincinnati</u>, <u>Ohio 45242</u>, (the "<u>Assignor</u>"), desires to assign the entire right, title and interest in and to the Inventions and Assigned Patents (each, as defined below) to <u>EvePoint Pharmaceuticals</u>, <u>Inc.</u>, a corporation incorporated under the laws of the of Delaware, having a place of business at 480 Pleasant Street, Suite A-210, Watertown, MA 02472, (the "<u>Assignee</u>"), and Assignee desires to acquire such right, title and interest, all on the terms and conditions set forth in this Patent Assignment.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Assignor to have been received in full from said Assignee:

- 1. Said Assignor has obtained the entire right, title and interest in and to certain new and useful inventions and improvements disclosed in the following patent(s) and patent application(s) listed in ATTACHMENTS A, B, and C (the "Listed Patent(s)"). As used herein: "Assigned Patents" means (a) the Listed Patent(s), (b) all Patents that share priority with or claim priority to or from the Listed Patent(s), including each and every Patent that is a divisional, substitution, continuation, continuation-in-part, non-provisional, or national phase application of any of the Listed Patent(s), (c) all Patents applied for on an invention disclosed within the Patents included in foregoing subclauses (a)-(b), (d) each and every Patent granting, issuing or reissuing from any of the foregoing under subclauses (a)-(d), and (f) each and every Patent filed outside the United States and corresponding to any of the foregoing under subclauses (a)-(e). "Patents" means (i) patents, certifications of inventions, inventor's certificates and other forms of protection granted on any invention in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise, and (ii) applications therefor (whether provisional, converted provisional, utility, design, plant, utility model, non-provisional or otherwise).
- 2. Said Assignor does hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to the Assigned Patents, including the right to claim priority to and from said Assigned Patents; (b) in and to the inventions disclosed in the Assigned Patents, and in and to all embodiments of the inventions (the "Inventions") and (c) in and to all claims for past, present and future infringement of the Assigned Patents, including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Assigned Patents.
- 3. Said Assignor hereby covenants and agrees to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Assignor shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for filing, prosecuting or maintaining any of the Assigned Patents; (c) for filing, prosecuting or maintaining applications for reissuance of any said Assigned Patents; (d) for interference or other priority proceedings involving said Assigned Patents or Inventions; and (e) for legal proceedings involving said Inventions or Assigned Patents, including without limitation reissues and reexaminations, IPRs, opposition and other post-grant proceedings, cancellation proceedings, priority contests, derivation proceedings, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Assignor in providing such cooperation shall be paid for by said Assignee.
- 4. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, and assigns, and shall be binding upon said Assignor, its successors and its assigns.
- 5. Said Assignor hereby warrants, represents and covenants that Assignor has not entered and will not enter into any assignment, contract, or understanding in conflict herewith, and that Assignor's predecessors have not entered into any assignment, contract or understanding in conflict herewith.
- 6. Said Assignor hereby requests that any Assigned Patents issuing or granting in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued or granted in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors and assigns.
- 7. This instrument will be interpreted and construed in accordance with the laws of the Commonwealth of Massachusetts, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

ACTIVE/111122520.9

CORPORATE TO CORPORATE PATENT ASSIGNMENT

Docket Number 45725-700

IN WITNESS WHEREOF, said Assignor has executed and delivered this instrument to said Assignee as of the date written below:

AGREED TO BY ASSIGNOR:

Aerpio Pharmaceuticals, Inc.

---- DocuSigned by:

Date: August 26, 2021

Signature: Neil Vesai
Name: Neil Desai

Title: Authorized Signatory

RECEIVED AND AGREED TO BY ASSIGNEE:

EyePoint Pharmaceuticals, Inc.

Date: August 26, 2021 Signature:

Name: George Elston

Title: Chief Financial Officer and Head of Corporate Development

CORPORATE TO CORPORATE PATENT ASSIGNMENT

Docket Number 45725-700

IN WITNESS WHEREOF, said Assignor has executed and delivered this instrument to said Assignee as of the date written below:

AGREED TO BY ASSIGNOR:

Aerpio Pharmaceuticals, Inc.

Date: August 26, 2021 Signature:

Name: Neil Desai

Title: Authorized Signatory

RECEIVED AND AGREED TO BY ASSIGNEE:

EyePoint Pharmaceuticals, Inc.

--- DocuSigned by:

Date: August 26, 2021

Signature: George Elston

Name: George ERRER 6804F0...
Title: Chief Financial Officer and Head of Corporate Development

ACTIVE/111122520.9

ATTACHMENT A

Country	Application No.	Filing Date	Patent No.	Patent Date	Title
United States	60/816,730	06/27/2006			HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States	60/816,731	06/27/2006			HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States	60/816,825	06/27/2006			HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States	11/823,086	06/26/2007	7,622,593	11/24/200 9	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States	11/821,846	06/26/2007	7,795,444	09/14/201	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States	11/821,868	06/26/2007	7,589,212	09/15/200	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States	12/624,072	11/23/2009	8,258,311	09/04/201	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States	13/309,452	12/01/2011	8,338,615	12/25/201	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States	13/691,757	12/01/2012	8,946,232	02/03/201	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States	13/936,450	07/08/2013	8,895,563	11/25/201 4	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States	13/309,445	12/01/2011	8,329,916	12/11/201	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
United States	14/569,106	12/12/2014	9,126,958	09/08/201	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

ACTIVE/111122520.9

United States	United States	nited States	14/252,140	04/14/2014	9,284,285	03/15/201	HUMAN PROTEIN
United States	United States	inted States	1 1/232,1 10	01/11/2011	7,201,203		
United States	United States						
United States	United States						
United States	TYROSINE PHOSPHATI	nited States	15/016 599	02/05/2016	9 795 594	10/24/201	
United States	United States	inted States	15/010,577	02/03/2010	,,,,,,,,,		
United States	United States 15/705,639 09/15/2017 10,463,650 11/05/201 HUMAN PROTEIN TYROSINE PHOSPHATINHIBITORS AND METHODS OF USE United States 16/577,808 09/20/2019 HUMAN PROTEIN TYROSINE PHOSPHATINHIBITORS AND METHODS OF USE United States 17/096,548 11/12/2020 HUMAN PROTEIN TYROSINE PHOSPHATINHIBITORS AND METHODS OF USE United States 12/558,169 09/11/2009 HUMAN PROTEIN TYROSINE PHOSPHATINHIBITORS AND METHODS OF USE United States 12/850,026 08/04/2010 8,106,078 01/31/201 HUMAN PROTEIN TYROSINE PHOSPHATINHIBITORS AND METHODS OF USE United States 12/850,026 08/04/2010 8,106,078 01/31/201 HUMAN PROTEIN TYROSINE PHOSPHATINHIBITORS AND METHODS OF USE United States 12/850,026 08/04/2010 8,106,078 01/31/201 HUMAN PROTEIN TYROSINE PHOSPHATINHIBITORS AND METHODS OF USE United States 12/467,430 05/18/2009 8,188,125 05/29/201 HUMAN PROTEIN					,	
United States 15/705,639 09/15/2017 10,463,650 11/05/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE P	United States						
United States	9 TYROSINE PHOSPHATI INHIBITORS AND METHODS OF USE	nited States	15/705 639	09/15/2017	10.463.650	11/05/201	
United States	INHIBITORS AND METHODS OF USE	mica states	13/703,037	05/15/2017	10,405,050		
United States	United States 16/577,808 09/20/2019 HUMAN PROTEIN TYROSINE PHOSPHATI INHIBITORS AND METHODS OF USE United States 17/096,548 11/12/2020 HUMAN PROTEIN TYROSINE PHOSPHATI INHIBITORS AND METHODS OF USE United States 12/558,169 09/11/2009 HUMAN PROTEIN TYROSINE PHOSPHATI INHIBITORS AND METHODS OF USE United States 12/850,026 08/04/2010 8,106,078 01/31/201 HUMAN PROTEIN TYROSINE PHOSPHATI INHIBITORS AND METHODS OF USE United States 12/850,026 08/04/2010 8,106,078 01/31/201 HUMAN PROTEIN TYROSINE PHOSPHATI INHIBITORS AND METHODS OF USE United States 12/467,430 05/18/2009 8,188,125 05/29/201 HUMAN PROTEIN						
United States	United States						
United States	TYROSINE PHOSPHATI INHIBITORS AND METHODS OF USE	nited States	16/577 808	09/20/2019			
United States	INHIBITORS AND METHODS OF USE	inicu states	10/577,000	05/20/2015			
United States	METHODS OF USE						
United States	United States 17/096,548 11/12/2020						
TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE H	TYROSINE PHOSPHATI	nited States	17/006 548	11/12/2020			
United States	INHIBITORS AND METHODS OF USE	inted States	17/090,348	11/12/2020			
United States	United States 12/558,169 09/11/2009 HUMAN PROTEIN TYROSINE PHOSPHATI INHIBITORS AND METHODS OF USE United States 12/850,026 08/04/2010 8,106,078 01/31/201 HUMAN PROTEIN TYROSINE PHOSPHATI INHIBITORS AND METHODS OF USE United States 12/467,430 05/18/2009 8,188,125 05/29/201 HUMAN PROTEIN						
United States	United States 12/558,169 09/11/2009 HUMAN PROTEIN TYROSINE PHOSPHATI INHIBITORS AND METHODS OF USE United States 12/850,026 08/04/2010 8,106,078 01/31/201 HUMAN PROTEIN TYROSINE PHOSPHATI INHIBITORS AND METHODS OF USE United States 12/467,430 05/18/2009 8,188,125 05/29/201 HUMAN PROTEIN						
United States Un	TYROSINE PHOSPHATI INHIBITORS AND METHODS OF USE	nitad Statas	12/559 160	00/11/2000			
United States	INHIBITORS AND METHODS OF USE	mied States	12/338,109	09/11/2009			
United States	United States 12/850,026 08/04/2010 8,106,078 01/31/201 HUMAN PROTEIN 2 TYROSINE PHOSPHATI INHIBITORS AND METHODS OF USE United States 12/467,430 05/18/2009 8,188,125 05/29/201 HUMAN PROTEIN						
United States	United States 12/850,026 08/04/2010 8,106,078 01/31/201 HUMAN PROTEIN TYROSINE PHOSPHATI INHIBITORS AND METHODS OF USE United States 12/467,430 05/18/2009 8,188,125 05/29/201 HUMAN PROTEIN						
United States	2 TYROSINE PHOSPHATI INHIBITORS AND METHODS OF USE United States 12/467,430 05/18/2009 8,188,125 05/29/201 HUMAN PROTEIN	wite d Ctates	12/950 026	00/04/2010	9.106.079	01/21/201	
United States	INHIBITORS AND METHODS OF USE United States 12/467,430 05/18/2009 8,188,125 05/29/201 HUMAN PROTEIN	mited States	12/850,026	08/04/2010	8,106,078		
United States	United States 12/467,430 05/18/2009 8,188,125 05/29/201 HUMAN PROTEIN					2	
United States	United States 12/467,430 05/18/2009 8,188,125 05/29/201 HUMAN PROTEIN						
United States			12/4/7 420	05/10/2000	0.100.125	05/20/201	
INHIBITORS AND METHODS OF USE		mied States	12/46/,430	05/18/2009	8,188,123		
METHODS OF USE						2	
United States							
United States			12//2/ 500	00/25/2012			
INHIBITORS AND METHODS OF USE		nited States	13/626,590	09/25/2012			
United States 13/626,614 09/25/2012 8,846,685 09/30/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE United States 14/938,526 11/11/2015 RE46,592 10/31/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE WO PCT/US2007/0148 06/27/2007 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE WO PCT/US2007/0148 06/27/2007 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE WO PCT/US2007/0148 06/27/2007 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE WO PCT/US2007/0148 06/27/2007 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE WO PCT/US2007/0148 06/27/2007 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE							
United States							
4 TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE		1. 1.0.	10/00/ (11	00/05/0010	0.046.607	00/20/201	
INHIBITORS AND METHODS OF USE		nited States	13/626,614	09/25/2012	8,846,685		
United States						4	
United States 14/938,526 11/11/2015 RE46,592 10/31/201 TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE WO PCT/US2007/0148 06/27/2007 TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE WO PCT/US2007/0148 06/27/2007 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE WO PCT/US2007/0148 06/27/2007 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE WO PCT/US2007/0148 06/27/2007 HUMAN PROTEIN							
7 TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE		1.0	4.4000 #0.4	44446045	7716 702	10/21/201	
INHIBITORS AND METHODS OF USE		nited States	14/938,526	11/11/2015	RE46,592		
METHODS OF USE						7	
WO PCT/US2007/0148 06/27/2007 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE WO PCT/US2007/0148 06/27/2007 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE WO PCT/US2007/0148 06/27/2007 HUMAN PROTEIN							
TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE				0.515=1-			
INHIBITORS AND METHODS OF USE		WO		06/27/2007			
METHODS OF USE			22				
WO PCT/US2007/0148 06/27/2007 HUMAN PROTEIN 23 TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE WO PCT/US2007/0148 06/27/2007 HUMAN PROTEIN							
23 TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE WO PCT/US2007/0148 06/27/2007 HUMAN PROTEIN							
WO PCT/US2007/0148 06/27/2007 INHIBITORS AND METHODS OF USE HUMAN PROTEIN		WO		06/27/2007			
WO PCT/US2007/0148 06/27/2007 METHODS OF USE HUMAN PROTEIN			23				
WO PCT/US2007/0148 06/27/2007 HUMAN PROTEIN							
24 TVDACINE DUACDUATE		WO		06/27/2007			
24	24 TYROSINE PHOSPHATI		24				TYROSINE PHOSPHATE
				I	I	I	

					INHIBITORS AND
					METHODS OF USE
Europe	7809907.4	06/27/2007	2041102	11/12/201	HUMAN PROTEIN
				4	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Europe	12196174.2	06/27/2007	2592072	09/20/201	HUMAN PROTEIN
				7	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Europe	17191765.1	06/27/2007	3323815	10/07/202	HUMAN PROTEIN
				0	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Europe	07809908.2	06/27/2007	2038265	03/18/201	HUMAN PROTEIN
				5	TYROSINE PHOSPHATE
					INHIBITORS AND
	121045	0.5/0.5/0.00	2502052	00/00/00/	METHODS OF USE
Europe	12196179.1	06/27/2007	2592073	08/30/201	HUMAN PROTEIN
				7	TYROSINE PHOSPHATE
					INHIBITORS AND
	17107010.0	06/07/0007			METHODS OF USE
Europe	17187910.9	06/27/2007			HUMAN PROTEIN
					TYROSINE PHOSPHATE
					INHIBITORS AND
F	07000000	06/27/2007	2041120	00/02/201	METHODS OF USE
Europe	07809909.0	06/27/2007	2041129	09/03/201	HUMAN PROTEIN
				4	TYROSINE PHOSPHATE INHIBITORS AND
					METHODS OF USE
Europe	14166121.5	06/27/2007	2803663	11/29/201	HUMAN PROTEIN
Europe	14100121.3	00/2//2007	2803003	7	TYROSINE PHOSPHATE
				/	INHIBITORS AND
					METHODS OF USE
Europe	17182516.9	06/27/2007			HUMAN PROTEIN
Larope	17102310.9	00/2//2007			TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Germany	07809909.0	06/27/2007	2041129	09/03/201	HUMAN PROTEIN
				4	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Germany	12196174.2	06/27/2007	602007052	09/20/201	HUMAN PROTEIN
-			457.1	7	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Germany	602007052232.3	06/27/2007	2592073	08/30/201	HUMAN PROTEIN
-				7	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Germany	602007053259.0	06/27/2007	2803663	11/29/201	HUMAN PROTEIN
				7	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE

Germany	17191765.1	06/27/2007	3323815	10/07/202	HUMAN PROTEIN
Germany	1/191/03.1	00/2//2007	3323613	0	TYROSINE PHOSPHATE
					INHIBITORS AND
C	07900007.4	06/27/2007	3043163	11/12/201	METHODS OF USE
Germany	07809907.4	06/27/2007	2041102	11/12/201	HUMAN PROTEIN
				4	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Germany	07809908.2	06/27/2007	2038265	03/18/201	HUMAN PROTEIN
				5	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
France	07809909.0	06/27/2007	2041129	09/03/201	HUMAN PROTEIN
				4	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
France	12196174.2	06/27/2007	2592072	09/20/201	HUMAN PROTEIN
				7	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
France	12196179.1	06/27/2007	2592073	08/30/201	HUMAN PROTEIN
				7	TYROSINE PHOSPHATE
				·	INHIBITORS AND
					METHODS OF USE
France	14166121.5	06/27/2007	2803663	11/29/201	HUMAN PROTEIN
	14100121.3	00/2//2007	2003003	7	TYROSINE PHOSPHATE
				′	INHIBITORS AND
					METHODS OF USE
France	17191765.1	06/27/2007	3323815	10/07/202	HUMAN PROTEIN
Plance	1/191/05.1	00/2//2007	3323613	0	TYROSINE PHOSPHATE
					INHIBITORS AND
F	0700007.4	06/07/0007	2041102	11/12/201	METHODS OF USE
France	07809907.4	06/27/2007	2041102	11/12/201	HUMAN PROTEIN
				4	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
France	7809908.2	06/27/2007	2038265	03/18/201	HUMAN PROTEIN
				5	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
United	07809909.0	06/27/2007	2041129	09/03/201	HUMAN PROTEIN
Kingdom				4	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
United	12196179.1	06/27/2007	2592073	08/30/201	HUMAN PROTEIN
Kingdom				7	TYROSINE PHOSPHATE
-					INHIBITORS AND
					METHODS OF USE
United	12196174.2	06/27/2007	2592072	09/20/201	HUMAN PROTEIN
Kingdom				7	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
United	14166121.5	06/27/2007	2803663	11/29/201	HUMAN PROTEIN
Kingdom	1.100121.0			7	TYROSINE PHOSPHATE
				'	
				1	

		1		1	DHIIDITODG AND
					INHIBITORS AND
					METHODS OF USE
United	17191765.1	06/27/2007	3323815	10/07/202	HUMAN PROTEIN
Kingdom				0	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
United	07809907.4	06/27/2007	2041102	11/12/201	HUMAN PROTEIN
Kingdom				4	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
United	07809908.2	06/27/2007	2038265	03/18/201	HUMAN PROTEIN
Kingdom				5	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Austria	07809909.0	06/27/2007	2041129	09/03/201	HUMAN PROTEIN
7 tustria	07007707.0	00/2//2007	2041127	4	TYROSINE PHOSPHATE
				1	INHIBITORS AND
					METHODS OF USE
A	0700007.4	06/27/2007	2041102	11/12/201	
Austria	07809907.4	06/27/2007	2041102	11/12/201	HUMAN PROTEIN
				4	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Austria	07809908.2	06/27/2007	2038265	03/18/201	HUMAN PROTEIN
				5	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Austria	12196174.2	06/27/2007	2592072	09/20/201	HUMAN PROTEIN
				7	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Austria	14166121.5	06/27/2007	2803663	11/29/200	HUMAN PROTEIN
				7	TYROSINE PHOSPHATE
				·	INHIBITORS AND
					METHODS OF USE
Austria	17191765.1	06/27/2007	3323815	10/07/202	HUMAN PROTEIN
7 rustria	17171703.1	00/2//2007	3323013	0	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Belgium	07809909.0	06/27/2007	2041129	09/03/201	HUMAN PROTEIN
Beigiuiii	0/809909.0	00/2//2007	2041129		
				4	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Belgium	07809907.4	06/27/2007	2041102	11/12/201	HUMAN PROTEIN
				4	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Belgium	07809908.2	06/27/2007	2038265	03/18/201	HUMAN PROTEIN
				5	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Belgium	07809909.0	06/27/2007	2592072	09/20/201	HUMAN PROTEIN
				7	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
		ı			MILITIODS OF OSL

Belgium	07809907.4	06/27/2007	2803663	11/29/201	HUMAN PROTEIN
Beigium	07007707.4	00/2//2007	2803003	7	TYROSINE PHOSPHATE
				/	INHIBITORS AND
					METHODS OF USE
Belgium	17191765.1	06/27/2007	3323815	10/07/202	HUMAN PROTEIN
Beigium	1/191/03.1	00/2//2007	3323613	0	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Bulgaria	07809909.0	06/27/2007	2041129	09/03/201	HUMAN PROTEIN
Duigana	07809909.0	00/2//2007	2041129	4	TYROSINE PHOSPHATE
				4	INHIBITORS AND
					METHODS OF USE
Bulgaria	7809907.4	06/27/2007	2041102	11/12/201	HUMAN PROTEIN
Duigana	/00990/.4	00/2//2007	2041102	4	TYROSINE PHOSPHATE
				4	INHIBITORS AND
					METHODS OF USE
D-1-ania	07809908.2	06/27/2007	2038265	03/18/201	HUMAN PROTEIN
Bulgaria	0/809908.2	00/2//2007	2038203		TYROSINE PHOSPHATE
				5	INHIBITORS AND
T itter a min	07900000	06/27/2007	2041129	00/02/201	METHODS OF USE
Lithuania	07809909.0	06/27/2007	2041129	09/03/201	HUMAN PROTEIN
				4	TYROSINE PHOSPHATE
					INHIBITORS AND
T 1.1	0700007.4	06/27/2007	2041102	11/12/201	METHODS OF USE
Lithuania	07809907.4	06/27/2007	2041102	11/12/201	HUMAN PROTEIN
				4	TYROSINE PHOSPHATE
					INHIBITORS AND
T '41 '	07000000	06/27/2007	2020265	02/10/201	METHODS OF USE
Lithuania	07809908.2	06/27/2007	2038265	03/18/201	HUMAN PROTEIN
				5	TYROSINE PHOSPHATE
					INHIBITORS AND
T	07000000	0.6/0.7/0.007	2041120	00/02/201	METHODS OF USE
Latvia	07809909.0	06/27/2007	2041129	09/03/201	HUMAN PROTEIN
				4	TYROSINE PHOSPHATE
					INHIBITORS AND
T	0700007.4	0.6/0.7/0.007	2041102	11/12/201	METHODS OF USE
Latvia	07809907.4	06/27/2007	2041102	11/12/201	HUMAN PROTEIN
				4	TYROSINE PHOSPHATE
					INHIBITORS AND
	07000000	0.6/0.7/0.007	2020265	02/10/201	METHODS OF USE
Latvia	07809908.2	06/27/2007	2038265	03/18/201	HUMAN PROTEIN
				5	TYROSINE PHOSPHATE
					INHIBITORS AND
G :: 1 1	7 000000	0.6/25/2005	2041120	00/02/201	METHODS OF USE
Switzerland	7809909	06/27/2007	2041129	09/03/201	HUMAN PROTEIN
				4	TYROSINE PHOSPHATE
					INHIBITORS AND
G 4 . 1 1	700007.4	06/07/0007	2041102	11/10/201	METHODS OF USE
Switzerland	7809907.4	06/27/2007	2041102	11/12/201	HUMAN PROTEIN
				4	TYROSINE PHOSPHATE
					INHIBITORS AND
Ci41 1	07000000	06/27/2027	2020265	02/10/201	METHODS OF USE
Switzerland	07809908.2	06/27/2007	2038265	03/18/201	HUMAN PROTEIN
				5	TYROSINE PHOSPHATE

					INHIBITORS AND METHODS OF USE
Switzerland	12196174.2	06/27/2007	2592072	09/20/201 7	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Switzerland	14166121.5	06/27/2007	2803663	11/20/201 7	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Switzerland	17191765.1	06/27/2007	3323815	0	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Cyprus	07809909.0	06/27/2007	2041129	09/03/201	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Cyprus	07809907.4	06/27/2007	2041102	11/12/201 4	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Cyprus	07809908.2	06/27/2007	2038265	03/18/201	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Czech Republic	07809909.0	06/27/2007	2041129	09/03/201	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Czech Republic	07809907.4	06/27/2007	2041102	11/12/201 4	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Czech Republic	07809908.2	06/27/2007	2038265	03/18/201	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Czech Republic	12196174.2	06/27/2007	2592072	09/20/201 7	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Denmark	07809909.0	06/27/2007	2041129	09/03/201	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Denmark	07809907.4	06/27/2007	2041102	11/12/201 4	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Denmark	07809908.2	06/27/2007	2038265	03/18/201	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

Denmark
Denmark
Estonia 07809909.0 06/27/2007 2041129 09/03/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE Estonia 07809907.4 06/27/2007 2041102 11/12/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE Estonia 07809908.2 06/27/2007 2038265 03/18/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE Spain 07809909.0 06/27/2007 2041129 09/03/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE Spain 07809907.4 06/27/2007 2041102 11/12/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE Spain 07809908.2 06/27/2007 2041102 11/12/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE Spain 07809908.2 06/27/2007 2038265 03/18/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE Spain 12196174.2 06/27/2007 2592072 09/20/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE Spain 14166121.5 06/27/2007 2592072 09/20/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE Spain 17191765.1 06/27/2007 3323815 10/07/202 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE Finland 07809909.0 06/27/2007 2041129 09/03/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE Finland 07809909.0 06/27/2007 2041129 09/03/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE Finland 07809909.0 06/27/2007 2041129 09/03/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE Finland 07809909.0 06/27/2007 2041129 09/03/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE Finland 07809909.0 06/27/2007 2041129 109/03/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Estonia 07809909.0 06/27/2007 2041129 09/03/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Estonia 07809909.0 06/27/2007 2041129 09/03/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INH
Estonia 07809909.0 06/27/2007 2041129 09/03/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INH
Estonia
Estonia 07809907.4 06/27/2007 2041102 11/12/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE HOSPHATE INHIBITORS AND METHODS OF USE HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Estonia 07809907.4 06/27/2007 2041102 11/12/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE Estonia 07809908.2 06/27/2007 2038265 5 03/18/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE Spain 07809909.0 06/27/2007 2041129 09/03/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE Spain 07809907.4 06/27/2007 2041102 11/12/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE Spain 07809908.2 06/27/2007 2038265 03/18/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE Spain 12196174.2 06/27/2007 2038265 03/18/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE Spain 12196174.2 06/27/2007 2592072 09/20/201 TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE Spain 14166121.5 06/27/2007 2803663 11/29/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE Spain 17191765.1 06/27/2007 3323815 10/07/202 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE Finland 07809909.0 06/27/2007 2041129 09/03/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE Finland 07809909.0 06/27/2007 2041129 09/03/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE Finland 07809909.0 06/27/2007 2041129 09/03/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Estonia
Estonia 07809908.2 06/27/2007 2038265 03/18/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Estonia 07809908.2 06/27/2007 2038265 03/18/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Estonia 07809908.2 06/27/2007 2038265 03/18/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Estonia 07809908.2 06/27/2007 2038265 03/18/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Spain 07809909.0 06/27/2007 2041129 09/03/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Spain 07809909.0 06/27/2007 2041129 09/03/201
Spain 07809909.0 06/27/2007 2041129 09/03/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Spain 07809909.0 06/27/2007 2041129 09/03/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Spain 07809907.4 06/27/2007 2041102 11/12/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Spain 07809907.4 06/27/2007 2041102 11/12/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Spain 07809907.4 06/27/2007 2041102 11/12/201
Spain 07809907.4 06/27/2007 2041102 11/12/201
Spain 07809908.2 06/27/2007 2038265 03/18/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Spain 07809908.2 06/27/2007 2038265 03/18/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Spain 07809908.2 06/27/2007 2038265 03/18/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Spain
Spain 12196174.2 06/27/2007 2592072 09/20/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Spain 12196174.2 06/27/2007 2592072 09/20/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Spain 12196174.2 06/27/2007 2592072 09/20/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Spain
TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Spain 14166121.5 06/27/2007 2803663 11/29/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Spain
Spain 14166121.5 06/27/2007 2803663 11/29/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE Spain 17191765.1 06/27/2007 3323815 10/07/202 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE Finland 07809909.0 06/27/2007 2041129 09/03/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Spain 17191765.1 06/27/2007 3323815 10/07/202 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Spain 17191765.1 06/27/2007 3323815 10/07/202 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE Finland 07809909.0 06/27/2007 2041129 09/03/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Spain 17191765.1 06/27/2007 3323815 10/07/202 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE Finland 07809909.0 06/27/2007 2041129 09/03/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Finland 07809909.0 06/27/2007 2041129 09/03/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE 4 TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Finland 07809909.0 06/27/2007 2041129 09/03/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Finland 07809909.0 06/27/2007 2041129 09/03/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Finland 07809909.0 06/27/2007 2041129 09/03/201 HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
4 TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
INHIBITORS AND METHODS OF USE
METHODS OF USE
Finland 07809907.4 06/27/2007 2041102 11/12/201 HUMAN PROTEIN
4 TYROSINE PHOSPHATE

		1		1	DHIIDITODG AND
					INHIBITORS AND
					METHODS OF USE
Finland	07809908.2	06/27/2007	2038265	03/18/201	HUMAN PROTEIN
				5	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Finland	12196174.2	06/27/2007	2592072	09/20/201	HUMAN PROTEIN
				7	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Finland	14166121.5	06/27/2007	2803663	11/29/201	HUMAN PROTEIN
				7	TYROSINE PHOSPHATE
				·	INHIBITORS AND
					METHODS OF USE
Finland	17191765.1	06/27/2007	3323815	10/07/202	HUMAN PROTEIN
1 mana	1/1/1/05,1	00/2//2007	3323013	0	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Greece	07809909.0	06/27/2007	2041129	09/03/201	HUMAN PROTEIN
Gleece	0/809909.0	00/2//2007	2041129		TYROSINE PHOSPHATE
				4	
					INHIBITORS AND
	0700007.4	0.6/2.7/2.007	2011102	11/12/201	METHODS OF USE
Greece	07809907.4	06/27/2007	2041102	11/12/201	HUMAN PROTEIN
				4	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Greece	07809908.2	06/27/2007	2038265	03/18/201	HUMAN PROTEIN
				5	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Hungary	07809909.0	06/27/2007	2041129	09/03/201	HUMAN PROTEIN
				4	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Hungary	07809907.4	06/27/2007	2041102	11/12/201	HUMAN PROTEIN
				4	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Hungary	07809908.2	06/27/2007	2038265	03/18/201	HUMAN PROTEIN
				5	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Iceland	07809909.0	06/27/2007	2041129	09/03/201	HUMAN PROTEIN
Tociana	07007707.0	00/2//2007	2011127	4	TYROSINE PHOSPHATE
				,	INHIBITORS AND
					METHODS OF USE
Iceland	07809907.4	06/27/2007	2041102	11/12/201	HUMAN PROTEIN
iccialiu	0/00770/.4	00/2//2007	2041102	4	TYROSINE PHOSPHATE
					INHIBITORS AND
Inclass 1	07000000	06/07/0007	2022265	02/19/201	METHODS OF USE
Iceland	07809908.2	06/27/2007	2038265	03/18/201	HUMAN PROTEIN
				5	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE

Ireland	07809909.0	06/27/2007	2041129	09/03/201	HUMAN PROTEIN
neiand	07809909.0	00/2//2007	2041129	4	TYROSINE PHOSPHATE
				1	INHIBITORS AND
					METHODS OF USE
Ireland	07809907.4	06/27/2007	2041102	11/12/201	HUMAN PROTEIN
neiand	0/00990/.4	00/2//2007	2041102	4	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Ireland	07809908.2	06/27/2007	2038265	03/18/201	HUMAN PROTEIN
neiand	07809908.2	00/2//2007	2036203	5	TYROSINE PHOSPHATE
				3	INHIBITORS AND
					METHODS OF USE
Ireland	12196174.2	06/27/2007	2592072	09/20/201	HUMAN PROTEIN
ireiand	121901/4.2	06/2//2007	2392072		
				7	TYROSINE PHOSPHATE INHIBITORS AND
T11	1010/170 1	06/27/2007	2502072	00/20/201	METHODS OF USE
Ireland	12196179.1	06/27/2007	2592073	08/30/201	HUMAN PROTEIN
				7	TYROSINE PHOSPHATE
					INHIBITORS AND
7 1 1	14166101.7	0.5/27/2007	2002662	11/20/201	METHODS OF USE
Ireland	14166121.5	06/27/2007	2803663	11/29/201	HUMAN PROTEIN
				7	TYROSINE PHOSPHATE
					INHIBITORS AND
7 1 1	171017671	0.6/0.7/0.007	2222017	10/07/202	METHODS OF USE
Ireland	17191765.1	06/27/2007	3323815	10/07/202	HUMAN PROTEIN
				0	TYROSINE PHOSPHATE
					INHIBITORS AND
	.=	0.5/2-7/200-		00/02/201	METHODS OF USE
Italy	07809909.0	06/27/2007	2041129	09/03/201	HUMAN PROTEIN
				4	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Italy	07809907.4	06/27/2007	2041102	11/12/201	HUMAN PROTEIN
				4	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Italy	07809908.2	06/27/2007	2038265	03/18/201	HUMAN PROTEIN
				5	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Italy	12196174.2	06/27/2007	2592072	09/20/201	HUMAN PROTEIN
				7	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Italy	12196179.1	06/27/2007	2592073	08/30/201	HUMAN PROTEIN
				7	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Italy	14166121.5	06/27/2007	2803663	11/29/201	HUMAN PROTEIN
				7	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Italy	17191765.1	06/27/2007	3323815	10/07/202	HUMAN PROTEIN
				0	TYROSINE PHOSPHATE
· · · · · · · · · · · · · · · · · · ·		·			

					INHIBITORS AND METHODS OF USE
Luxembourg	07809909.0	06/27/2007	2041129	09/03/201	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Luxembourg	7809907.4	06/27/2007	2041102	11/12/201	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Luxembourg	07809908.2	06/27/2007	2038265	03/18/201	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Malta	07809909.0	06/27/2007	2041129	09/03/201	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Malta	07809907.4	06/27/2007	2041102	11/12/201 4	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Malta	07809908.2	06/27/2007	2038265	03/18/201	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Monaco	07809909.0	06/27/2007	2041129	09/03/201	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Monaco	07809907.4	06/27/2007	2041102	11/12/201	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Monaco	07809908.2	06/27/2007	2038265	03/18/201	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Netherlands	07809909.0	06/27/2007	2041129	09/03/201	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Netherlands	07809907.4	06/27/2007	2041102	11/12/201	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Netherlands	07809908.2	06/27/2007	2038265	03/18/201	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE
Netherlands	12196174.2	06/27/2007	2592072	09/20/201 7	HUMAN PROTEIN TYROSINE PHOSPHATE INHIBITORS AND METHODS OF USE

Netherlands	14166121.5	06/27/2007	2803663	11/29/201	HUMAN PROTEIN
retheriands	14100121.5	00/2//2007	2003003	7	TYROSINE PHOSPHATE
				'	INHIBITORS AND
					METHODS OF USE
Netherlands	17191765.1	06/27/2007	3323815	10/07/202	HUMAN PROTEIN
1 10 110 110 110 110 110 110 110 110 11			002001	0	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Poland	07809909.0	06/27/2007	2041129	09/03/201	HUMAN PROTEIN
Totalia	07007707.0	00/2//2007	2011129	4	TYROSINE PHOSPHATE
				·	INHIBITORS AND
					METHODS OF USE
Poland	07809907.4	06/27/2007	2041102	11/12/201	HUMAN PROTEIN
Totalia	07007707.1	00/2//2007	20.1102	4	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Poland	07809908.2	06/27/2007	2038265	03/18/201	HUMAN PROTEIN
Toland	07007700.2	00/2//2007	2030203	5	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Poland	12196174.2	06/27/2007	2592072	09/20/201	HUMAN PROTEIN
1 Oland	12170174.2	00/2//2007	2372072	7	TYROSINE PHOSPHATE
				′	INHIBITORS AND
					METHODS OF USE
Poland	14166121.5	06/27/2007	2803663	11/29/201	HUMAN PROTEIN
Folalid	14100121.3	00/2//2007	2803003	7	TYROSINE PHOSPHATE
				/	INHIBITORS AND
					METHODS OF USE
Poland	17191765.1	06/27/2007	3323815	10/07/202	HUMAN PROTEIN
roianu	1/191/05.1	00/2//2007	3323613	0	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Portugal	07809909.0	06/27/2007	2041129	09/03/201	HUMAN PROTEIN
ronugai	07809909.0	00/2//2007	2041129	4	TYROSINE PHOSPHATE
				+	INHIBITORS AND
					METHODS OF USE
Portugal	07809907.4	06/27/2007	2041102	11/12/201	HUMAN PROTEIN
Portugar	0/80990/.4	00/2//2007	2041102	4	TYROSINE PHOSPHATE
				+	INHIBITORS AND
					METHODS OF USE
Portugal	07809908.2	06/27/2007	2038265	03/18/201	HUMAN PROTEIN
Fortugai	07009900.2	00/2//2007	2030203	5	TYROSINE PHOSPHATE
				3	INHIBITORS AND
					METHODS OF USE
Portugal	12196174.2	06/27/2007	2592072	09/20/201	HUMAN PROTEIN
Fortugai	121701/4.2	00/2//2007	2392072	7	TYROSINE PHOSPHATE
				′	INHIBITORS AND
					METHODS OF USE
Portugal	14166121.5	06/27/2007	2803663	11/29/201	HUMAN PROTEIN
ronugai	14100121.3	00/2//200/	2003003	7	TYROSINE PHOSPHATE
				'	INHIBITORS AND
Dortugo!	17191765.1	06/27/2007	3323815	10/07/202	METHODS OF USE
Portugal	1/191/03.1	00/2//200/	3343813	0	HUMAN PROTEIN TYROSINE PHOSPHATE
					I I RUSINE PHUSPHATE

		1		1	DHIIDIEODG AND
					INHIBITORS AND
					METHODS OF USE
Romania	07809909.0	06/27/2007	2041129	09/03/201	HUMAN PROTEIN
				4	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Romania	07809907.4	06/27/2007	2041102	11/12/201	HUMAN PROTEIN
				4	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Romania	07809908.2	06/27/2007	2038265	03/18/201	HUMAN PROTEIN
				5	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Sweden	07809909.0	06/27/2007	2041129	09/03/201	HUMAN PROTEIN
Sweden	07007707.0	00/2//2007	2041127	4	TYROSINE PHOSPHATE
				'	INHIBITORS AND
					METHODS OF USE
Sweden	07809907.4	06/27/2007	2041102	11/12/201	HUMAN PROTEIN
Sweden	0/80990/.4	00/2//2007	2041102	4	TYROSINE PHOSPHATE
				4	
					INHIBITORS AND
	0.7000000.0	0.6/0.7/0.007	2020267	02/10/201	METHODS OF USE
Sweden	07809908.2	06/27/2007	2038265	03/18/201	HUMAN PROTEIN
				5	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Sweden	12196174.2	06/27/2007	2592072	09/20/201	HUMAN PROTEIN
				7	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Sweden	14166121.5	06/27/2007	2803663	11/29/201	HUMAN PROTEIN
				7	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Sweden	17191765.1	06/27/2007	3323815	10/07/202	HUMAN PROTEIN
				0	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Slovenia	07809909.0	06/27/2007	2041129	09/03/201	HUMAN PROTEIN
				4	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Slovenia	07809907.4	06/27/2007	2041102	11/12/201	HUMAN PROTEIN
Sioveina	07007707.1	00/2//2007	2011102	4	TYROSINE PHOSPHATE
				,	INHIBITORS AND
					METHODS OF USE
Slovenia	07809908.2	06/27/2007	2038265	03/18/201	HUMAN PROTEIN
Sioveilla	0/007700.4	00/2//2007	2030203	5	TYROSINE PHOSPHATE
					INHIBITORS AND
C1===1 :-	07000000	06/27/2007	2041120	00/02/201	METHODS OF USE
Slovakia	07809909.0	06/27/2007	2041129	09/03/201	HUMAN PROTEIN
				4	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE

Slovakia	07809907.4	06/27/2007	2041102	11/12/201	HUMAN PROTEIN
Siovakia	0/00990/.4	00/2//2007	2041102	4	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Slovakia	07809908.2	06/27/2007	2038265	03/18/201	HUMAN PROTEIN
Siovakia	07809908.2	00/2//2007	2038203	5	TYROSINE PHOSPHATE
				3	INHIBITORS AND
					METHODS OF USE
T1	07809909.0	06/27/2007	TR 2014	09/03/201	
Turkey	0/809909.0	06/27/2007			HUMAN PROTEIN TYROSINE PHOSPHATE
			12834 T4	4	
					INHIBITORS AND
T1	0700007.4	06/27/2007	2041102	11/12/201	METHODS OF USE
Turkey	07809907.4	06/27/2007	2041102	11/12/201	HUMAN PROTEIN
				4	TYROSINE PHOSPHATE
					INHIBITORS AND
	.=			0.5 / 3.0 / 5.0 /	METHODS OF USE
Turkey	07809908.2	06/27/2007	TR 2015	03/18/201	HUMAN PROTEIN
			04305 T4	5	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Turkey	12196174.2	06/27/2007	2592072	09/20/201	HUMAN PROTEIN
				7	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Turkey	14166121.5	06/27/2007	2803663	11/29/201	HUMAN PROTEIN
				7	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Australia	2007265453	06/27/2007	200726545	05/03/201	HUMAN PROTEIN
			3	2	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Australia	2007265454	06/27/2007	200726545	02/09/201	HUMAN PROTEIN
			4	2	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Australia	2007265455	06/27/2007	200726545	02/23/201	HUMAN PROTEIN
			5	2	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Australia	2012200253	06/27/2007	201220025	10/18/201	HUMAN PROTEIN
			3	2	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Brazil	PI 0713570-0	06/27/2007			HUMAN PROTEIN
					TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Brazil	PI 0713357-0	06/27/2007			HUMAN PROTEIN
					TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Brazil	PI 0713349-9	06/27/2007			HUMAN PROTEIN
Diuzii	110/10017	00/2//2007			TYROSINE PHOSPHATE
			I	I	

		T	I	1	DILLIDITODE AND
					INHIBITORS AND
					METHODS OF USE
G 1	2 (57 00)	06/05/0005	2 (77 00)	01/01/001	THE CALL DE CORED I
Canada	2,657,096	06/27/2007	2,657,096	01/21/201	HUMAN PROTEIN
				4	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Canada	2,657,107	06/27/2007	2,657,107	01/07/201	HUMAN PROTEIN
				4	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Canada	2,656,915	06/27/2007	2,656,915	08/07/201	HUMAN PROTEIN
				2	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
China	200780030939.0	06/27/2007	ZL200780	08/08/201	HUMAN PROTEIN
			030939.0	2	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
China	200780030984.6	06/27/2007	ZL200780	10/30/201	HUMAN PROTEIN
		""	030984.6	3	TYROSINE PHOSPHATE
			050501.0		INHIBITORS AND
					METHODS OF USE
China	200780031040.0	06/27/2007	ZL200780	05/30/201	HUMAN PROTEIN
	200700031040.0	00/2//2007	031040.0	2	TYROSINE PHOSPHATE
			031040.0	2	INHIBITORS AND
					METHODS OF USE
Colombia	9007333	06/27/2007	3672		HUMAN PROTEIN
Colonibia	9007333	00/2//2007	3072		TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Calambia	0007224	06/27/2007	3673		
Colombia	9007334	06/27/2007	30/3		HUMAN PROTEIN
					TYROSINE PHOSPHATE
					INHIBITORS AND
G 1 1:	2007227	06/05/0005	2400	10/20/201	METHODS OF USE
Colombia	9007327	06/27/2007	2408	10/29/201	HUMAN PROTEIN
				2	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Hong Kong	09108319.8	06/27/2007	1129386	01/22/201	HUMAN PROTEIN
				6	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Hong Kong	13112445.1	06/27/2007			HUMAN PROTEIN
					TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Hong Kong	09108320.5	06/27/2007	1129387B	10/02/201	HUMAN PROTEIN
				5	TYROSINE PHOSPHATE
					INHIBITORS AND
		<u> </u>			METHODS OF USE
Hong Kong	13112446	06/27/2007			HUMAN PROTEIN
					TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
					10

Hong Kong	09108321.4	06/27/2007			HUMAN PROTEIN
Tiong Kong	03100321.4	00/2//2007			TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Hong Kong	15104703.3	06/27/2007			HUMAN PROTEIN
Hong Kong	13104/03.3	00/2//2007			TYROSINE PHOSPHATE
					INHIBITORS AND
T 1	107120	06/27/2007	10/120	11/20/201	METHODS OF USE
Israel	196128	06/27/2007	196128	11/30/201	HUMAN PROTEIN
				3	TYROSINE PHOSPHATE
					INHIBITORS AND
т 1	106120	06/25/2005	106120	06/05/001	METHODS OF USE
Israel	196129	06/27/2007	196129	06/25/201	HUMAN PROTEIN
				3	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Israel	196130	06/27/2007	196130	07/31/201	HUMAN PROTEIN
				4	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
India	515/DELNP/2009	06/27/2007	280469	02/22/201	HUMAN PROTEIN
				7	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
India	513/DELNP/2009	06/27/2007	289597	11/15/201	HUMAN PROTEIN
				7	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
India	512/DELNP/2009	06/27/2007			HUMAN PROTEIN
					TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Indonesia	W00200804210	06/27/2007	IDP000047	08/09/201	HUMAN PROTEIN
			234	7	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Indonesia	W-00200804213	06/27/2007	IDP000045	03/14/201	HUMAN PROTEIN
			140	7	TYROSINE PHOSPHATE
				·	INHIBITORS AND
					METHODS OF USE
Indonesia	W-00200804212	06/27/2007	IDP000040	12/21/201	HUMAN PROTEIN
	,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	"""	030	5	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Japan	2009-518226	06/27/2007	5232778	03/29/201	HUMAN PROTEIN
- apui				3	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Japan	2013-062411	06/27/2007	5860427	12/25/201	HUMAN PROTEIN
sapan	2013 002711	03,2772007	3000 127	5	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Japan	2009-518227	06/27/2007	5261383	05/02/201	HUMAN PROTEIN
Japan	2007-310227	00/2//2007	2201303	3	TYROSINE PHOSPHATE
					THOSHILIHOSHIAIL
		L	<u> </u>	<u> </u>	

					DILLIDITODE AND
					INHIBITORS AND
					METHODS OF USE
_	2012 020110	0.5/2=/200=			****
Japan	2013-029649	06/27/2007			HUMAN PROTEIN
					TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Japan	2015-178320	06/27/2007			HUMAN PROTEIN
					TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Japan	2015-178321	06/27/2007			HUMAN PROTEIN
1					TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Japan	2017-213854	06/27/2007			HUMAN PROTEIN
Jupun	2017 213021	00/2//2007			TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Japan	2017-213855	06/27/2007			HUMAN PROTEIN
Japan	2017-213633	00/2//2007			TYROSINE PHOSPHATE
					INHIBITORS AND
T	2000 710220	06/27/2007	5201740	02/22/201	METHODS OF USE
Japan	2009-518228	06/27/2007	5201740	02/22/201	HUMAN PROTEIN
				3	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Korea	10-2009-7001678	06/27/2007	1155365	06/05/201	HUMAN PROTEIN
				2	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Korea	10-2009-7001694	06/27/2007	1179087	08/28/201	HUMAN PROTEIN
				2	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Korea	2009-7001692	06/27/2007	1157844	06/13/201	HUMAN PROTEIN
				2	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Mexico	MX/a/2009/000288	06/27/2007	321351	06/24/201	HUMAN PROTEIN
				4	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Mexico	MX/a/2009/000289	06/27/2007	303155	09/06/201	HUMAN PROTEIN
	1.11 3 6 200 7 000 207	55,27,2007	505155	2	TYROSINE PHOSPHATE
				-	INHIBITORS AND
					METHODS OF USE
Mexico	MX/a/2009/000290	06/27/2007	279959	10/14/201	HUMAN PROTEIN
INICATO	1V12V1012UU7/UUU29U	00/2//2007	4 / 333 3	0	
				'	TYROSINE PHOSPHATE
					INHIBITORS AND
N 7 1	574407	06/07/2005	574107	06/05/201	METHODS OF USE
New Zealand	574407	06/27/2007	574407	06/05/201	HUMAN PROTEIN
				2	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE

New Zealand	574406	06/27/2007	574406	05/07/201	HUMAN PROTEIN
New Zealand	3/4400	00/2//2007	3/4400	2	TYROSINE PHOSPHATE
				2	INHIBITORS AND
					METHODS OF USE
New Zealand	574405	06/27/2007	574405	05/07/201	HUMAN PROTEIN
1 tow Zearana	271102	00/2//2007	371103	2	TYROSINE PHOSPHATE
					INHIBITORS AND
					METHODS OF USE
Philippines	1-2009-500031	06/27/2007	1-2009-	01/30/201	HUMAN PROTEIN
1 impplies	1-2007-300031	00/2//2007	500031	2	TYROSINE PHOSPHATE
			300031	2	INHIBITORS AND
					METHODS OF USE
Philippines	1-2009-500032	06/27/2007	1-2009-	05/07/201	HUMAN PROTEIN
	1-2007-300032	00/2//2007	500032	4	TYROSINE PHOSPHATE
			300032		INHIBITORS AND
					METHODS OF USE
Philippines	1-2009-500033	06/27/2007	1-2009-	07/31/201	HUMAN PROTEIN
rimppines	1-2009-300033	00/2//2007	500033	3	TYROSINE PHOSPHATE
			300033	3	INHIBITORS AND
					METHODS OF USE
Russian	2009102516	06/27/2007	2447065	12/10/201	HUMAN PROTEIN
	2009102316	00/2//2007	244/003		TYROSINE PHOSPHATE
Federation				1	
					INHIBITORS AND
Di.	2000102520	06/07/2007	2425762	12/10/201	METHODS OF USE
Russian	2009102538	06/27/2007	2435763	12/10/201	HUMAN PROTEIN
Federation				1	TYROSINE PHOSPHATE
					INHIBITORS AND
Danie	2009102537	06/27/2007	2430101	09/27/201	METHODS OF USE
Russian	2009102557	06/2//2007	2430101		HUMAN PROTEIN
Federation				1	TYROSINE PHOSPHATE
					INHIBITORS AND
G:	200000610.0	06/27/2007	140171	01/21/201	METHODS OF USE
Singapore	200809619-0	06/27/2007	149161	01/31/201	HUMAN PROTEIN
				2	TYROSINE PHOSPHATE
					INHIBITORS AND
Cinconono	200809621-6	06/27/2007	149904	07/20/201	METHODS OF USE
Singapore	200809621-6	06/27/2007	148804	07/29/201	HUMAN PROTEIN
				1	TYROSINE PHOSPHATE
					INHIBITORS AND
Cinnanana	200000622 4	06/27/2007	140005	07/29/201	METHODS OF USE
Singapore	200809622-4	06/27/2007	148805		HUMAN PROTEIN
				1	TYROSINE PHOSPHATE INHIBITORS AND
Caratta A Caira	2000/00550	06/27/2007	2000/0055	06/20/201	METHODS OF USE
South Africa	2009/00559	06/27/2007	2009/0055	06/30/201	HUMAN PROTEIN TYROSINE PHOSPHATE
			9	0	
					INHIBITORS AND
Courth A Suita	2000/00402	06/27/2007	2000/0040	06/20/201	METHODS OF USE
South Africa	2009/00492	00/2//200/	2009/0049	06/30/201	HUMAN PROTEIN
			2	0	TYROSINE PHOSPHATE
					INHIBITORS AND
Courth A frie	2000/00550	06/27/2007	2000/0055	04/24/201	METHODS OF USE
South Africa	2009/00558	06/27/2007	2009/0055	04/24/201	HUMAN PROTEIN
			8	2	TYROSINE PHOSPHATE

		1			D WITTE THOO D G A A D ID
					INHIBITORS AND METHODS OF USE
United States	61/144,022	01/12/2009			METHODS FOR TREATING VASCULAR LEAK SYNDROME
United States	61/184,986	06/08/2009			METHODS FOR TREATING VASCULAR LEAK SYNDROME
United States	14/075,809	11/08/2013			METHODS FOR TREATING VASCULAR LEAK SYNDROME
United States	15/443,353	02/27/2017			METHODS FOR TREATING VASCULAR LEAK SYNDROME
United States	16/719,317	12/18/2019			METHODS FOR TREATING VASCULAR LEAK SYNDROME
United States	15/930,583	05/13/2020			METHODS FOR TREATING VASCULAR LEAK SYNDROME
United States	13/968,269	08/15/2013			METHODS FOR TREATING VASCULAR LEAK SYNDROME
United States	13/724,396	12/21/2012	9,096,555	08/04/201	METHODS FOR TREATING VASCULAR LEAK SYNDROME
United States	12/677,512	03/22/2010			METHODS FOR TREATING VASCULAR LEAK SYNDROME
WO	PCT/US2010/0208 17	01/12/2010			METHODS FOR TREATING VASCULAR LEAK SYNDROME
Europe	10729682.4	01/12/2010	2385763	11/16/201	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Germany	10729682.4	01/12/2010	2385763	11/16/201	METHODS FOR TREATING VASCULAR LEAK SYNDROME
France	10729682.4	01/12/2010	2385763	11/16/201	METHODS FOR TREATING VASCULAR LEAK SYNDROME
United Kingdom	10729682.4	01/12/2010	2385763	11/16/201	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Austria	10729682.4	01/12/2010	2385763	04/18/201	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Belgium	10729682.4	01/12/2010	2385763	04/18/201	METHODS FOR TREATING VASCULAR LEAK SYNDROME

Switzerland	10729682.4	01/12/2010	2385763	04/18/201	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Denmark	10729682.4	01/12/2010	2385763	04/18/201	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Spain	10729682.4	01/12/2010	2385763	04/18/201	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Finland	10729682.4	01/12/2010	2385763	04/18/201 8	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Ireland	10729682.4	01/12/2010	2385763	s04/18/20 18	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Italy	10729682.4	01/12/2010	2385763	04/18/201 8	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Netherlands	10729682.4	01/12/2010	2385763	04/18/201 8	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Norway	10729682.4	01/12/2010	2385763	04/18/201 8	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Poland	10729682.4	01/12/2010	2385763	04/18/201 8	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Portugal	10729682.4	01/12/2010	2385763	04/18/201 8	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Sweden	10729682.4	01/12/2010	2385763	04/18/201	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Turkey	10729682.4	01/12/2010	2385763	04/18/201 8	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Australia	2010203352	01/12/2010	201020335	11/06/201 4	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Australia	2014202211	01/12/2010	201420221	09/15/201 6	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Australia	2016203254	01/12/2010	201620325 4	01/03/201	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Brazil	PI 1006898-8	01/12/2010			METHODS FOR TREATING VASCULAR LEAK SYNDROME
Canada	2,748,814	01/12/2010	2,748,814	02/25/201 4	METHODS FOR TREATING VASCULAR LEAK SYNDROME

Canada	2,838,846	01/12/2010	2,838,846	01/19/201	METHODS FOR TREATING VASCULAR LEAK SYNDROME
China	201080011867.7	01/12/2010			METHODS FOR TREATING VASCULAR LEAK SYNDROME
China	201810637424.7	01/12/2010			METHODS FOR TREATING VASCULAR LEAK SYNDROME
China	201910044287.0	01/12/2010			METHODS FOR TREATING VASCULAR LEAK SYNDROME
Hong Kong	12104707.2	01/12/2010			METHODS FOR TREATING VASCULAR LEAK SYNDROME
Indonesia	W00201102787	01/12/2010			METHODS FOR TREATING VASCULAR LEAK SYNDROME
Indonesia	P00201900995	01/12/2010			METHODS FOR TREATING VASCULAR LEAK SYNDROME
Israel	214047	01/12/2010	214047	02/01/201 7	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Israel	248340	01/12/2010	248340	12/21/201 8	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Israel	261374	01/12/2010			METHODS FOR TREATING VASCULAR LEAK SYNDROME
India	4961/DELNP/2011	01/12/2010			METHODS FOR TREATING VASCULAR LEAK SYNDROME
Japan	2011-545536	01/12/2010	5558489	06/13/201 4	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Japan	2014-116250	01/12/2010	5957035	06/24/201 6	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Korea	10-2011-7018768	01/12/2010	1495950	02/16/201	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Malaysia	PI 2011003558	01/12/2010	MY- 158804-A	11/15/201 6	METHODS FOR TREATING VASCULAR LEAK SYNDROME
Mexico	MX/a/2011/007419	01/12/2010	346984	04/07/201 7	METHODS FOR TREATING VASCULAR LEAK SYNDROME
New Zealand	594535	01/12/2010	594535	01/07/201	METHODS FOR TREATING VASCULAR LEAK SYNDROME

Philippines	1-2011-501369	01/12/2010			METHODS FOR
1 milppines	1-2011-301307	01/12/2010			TREATING VASCULAR
					LEAK SYNDROME
Russian	2011133833	01/12/2010	2539917		METHODS FOR
Federation	2011133033	01,12,2010	2337717		TREATING VASCULAR
reactation					LEAK SYNDROME
Russian	2014146121	01/12/2010			METHODS FOR
Federation	2011110121	01,12,2010			TREATING VASCULAR
					LEAK SYNDROME
Singapore	201104563-0	01/12/2010	172312		METHODS FOR
Singapore	20110.000 0	01,12,2010	1,2012	04/19/201	TREATING VASCULAR
				7	LEAK SYNDROME
Singapore	10201702247S	01/12/2010			METHODS FOR
Singapore	102017022170	01,12,2010			TREATING VASCULAR
					LEAK SYNDROME
South Africa	2011/05679	01/12/2010	2011/0567	04/25/201	METHODS FOR
South Thine	2011/02079	01,12,2010	9	2	TREATING VASCULAR
				_	LEAK SYNDROME
Thailand	1101001105	01/12/2010			METHODS FOR
	1101001105	01,12,2010			TREATING VASCULAR
					LEAK SYNDROME
Vietnam	1-2011-01745	01/12/2010			COMPOUNDS THAT
, 14411111	1 2011 01. 10	01,12,2010			INHIBIT THE
					INTRACELLULAR
					CATALYTIC SITE OF
					PROTEIN TYROSINE
					PHOSPHATASE BETA
					(PTP-B) MOLECULE AND
					COMPOSITIONS
					COMPRISING THE SAME
United States	61/223,260	07/06/2009			COMPOUNDS,
					COMPOSITIONS, AND
					METHODS FOR
					PREVENTING
					METASTASIS OF CANCER
					CELLS
United States	13/783,311	03/03/2013	8,883,832	11/11/201	COMPOUNDS,
				4	COMPOSITIONS, AND
					METHODS FOR
					PREVENTING METASTASIS OF CANCER
					CELLS
United States	14/272,689	05/08/2014	9,174,950	11/03/201	COMPOUNDS,
Office States	14/2/2,009	05/06/2014	9,174,950	5	COMPOSITIONS, AND
					METHODS FOR
					PREVENTING
					METASTASIS OF CANCER
					CELLS
United States	14/864,462	09/24/2015	9,949,956		COMPOUNDS,
			, ,	04/24/201	COMPOSITIONS, AND
				8	METHODS FOR
					PREVENTING
					METASTASIS OF CANCER
					CELLS

United States	15/913,392	03/06/2018			COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
United States	16/582,619	09/25/2019			COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
United States	12/677,550	12/01/2010	8,569,348	10/29/201	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
WO	PCT/US2010/0208 22	01/12/2010			COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Europe	10797461.0	01/12/2010	2451279	03/13/201	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Europe	19159755.8	01/12/2010			COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Germany	10797461.0	01/12/2010	60 2010 057 581.0	03/13/201	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
France	10797461.0	01/12/2010	2451279	03/13/201	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
United Kingdom	10797461.0	01/12/2010	2451279	03/13/201	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS

Austria	10797461.0	01/12/2010	2451279	03/13/201	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Belgium	10797461.0	01/12/2010	2451279	03/13/201	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Switzerland	10797461.0	01/12/2010	2451279	03/13/201	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Denmark	10797461.0	01/12/2010	2451279	03/13/201	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Spain	10797461.0	01/12/2010	2451279	03/13/201	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Finland	10797461.0	01/12/2010	2451279	03/13/201	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Ireland	10797461.0	01/12/2010	2451279	03/13/201	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Italy	10797461.0	01/12/2010	2451279	03/13/201	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Netherlands	10797461.0	01/12/2010	2451279	03/13/201	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS

Norway	10797461.0	01/12/2010	2451279	03/13/201 9	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Poland	10797461.0	01/12/2010	2451279	03/13/201 9	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Portugal	10797461.0	01/12/2010	2451279	03/13/201	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Sweden	10797461.0	01/12/2010	2451279	03/13/201	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Turkey	10797461.0	01/12/2010	2451279	03/13/201	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Australia	2010271105	01/12/2010	201027110	08/28/201	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Brazil	PI 1006897-0	01/12/2010			COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Canada	2,748,765	01/12/2010	2,748,765	07/22/201 4	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
China	201080012192.8	01/12/2010			COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS

	Γ	T	ı	I	
China	201410144271.4	01/12/2010			COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
China	201510713404.X	01/12/2010			COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Hong Kong	12105753.2	01/12/2010			COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Israel	214048	01/12/2010	214048	03/01/201	COMPOSITIONS FOR PREVENTING METASTASIS OF MELANOMA OR LUNG CANCER
Israel	248514	01/12/2010			COMPOSITIONS FOR PREVENTING METASTASIS OF MELANOMA OR LUNG CANCER
India	5406/DELNP/2011	01/12/2010			COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Indonesia	W00201102788	01/12/2010	IDP000045 935	05/18/201 7	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Japan	2011-554058	01/12/2010	5536113	05/09/201 4	COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Japan	2014-048238	01/12/2010			COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS
Japan	2015-183047	01/12/2010			COMPOUNDS, COMPOSITIONS, AND METHODS FOR

	Г	ı	ı	T	
					PREVENTING
					METASTASIS OF CANCER
					CELLS
Japan	2017-80657	01/12/2010	6505153	04/05/201	COMPOUNDS,
				9	COMPOSITIONS, AND
					METHODS FOR
					PREVENTING
					METASTASIS OF CANCER
					CELLS
Japan	2019-58234	01/12/2010			COMPOUNDS,
					COMPOSITIONS, AND
					METHODS FOR
					PREVENTING
					METASTASIS OF CANCER
					CELLS
Korea	2011-7018742	01/12/2010	10-	07/28/201	COMPOUNDS,
		,,	1426125	4	COMPOSITIONS, AND
			1120120		METHODS FOR
					PREVENTING
					METASTASIS OF CANCER
					CELLS
Malaysia	PI 2011003556	01/12/2010	MY-	03/15/201	COMPOUNDS,
1 Talay Sia	112011000000	01,12,2010	160399-A	7	COMPOSITIONS, AND
			100333771	,	METHODS FOR
					PREVENTING
					METASTASIS OF CANCER
					CELLS
Mexico	MX/a/2011/007420	01/12/2010	328717	03/20/201	COMPOUNDS,
IVICATEO	14114120117007120	01/12/2010	320717	5	COMPOSITIONS, AND
					METHODS FOR
					PREVENTING
					METASTASIS OF CANCER
					CELLS
New Zealand	594537	01/12/2010	594537	05/01/201	COMPOUNDS,
				4	COMPOSITIONS, AND
					METHODS FOR
					PREVENTING
					METASTASIS OF CANCER
					CELLS
Philippines	1-2011-501370	01/12/2010	1-2011-	07/21/201	COMPOUNDS,
1 imppines	2011 301370	01,12,2010	501370	7	COMPOSITIONS, AND
			301370	,	METHODS FOR
					PREVENTING
					METASTASIS OF CANCER
					CELLS
Russian	2011133835	01/12/2010	2519123		COMPOUNDS,
Federation	2011133033	01/12/2010	2317123		COMPOSITIONS, AND
					METHODS FOR
					PREVENTING
					METASTASIS OF CANCER
					CELLS
Singapore	201104564-8	01/12/2010			COMPOUNDS,
Singapore	2011013010				COMPOSITIONS, AND
					METHODS FOR
					PREVENTING
	l .	l	I	I	1100 (11111110

					METASTASIS OF CANCER
					CELLS
Singapore	10201505672T	01/12/2010			COMPOUNDS,
					COMPOSITIONS, AND
					METHODS FOR
					PREVENTING
					METASTASIS OF CANCER
					CELLS
South Africa	2011/05678	01/12/2010	2011/0567	04/25/201	COMPOUNDS,
			8	2	COMPOSITIONS, AND
			_	_	METHODS FOR
					PREVENTING
					METASTASIS OF CANCER
					CELLS
Thailand	1101001097	01/12/2010			COMPOUNDS,
Thanana	1101001077	01,12,2010			COMPOSITIONS, AND
					METHODS FOR
					PREVENTING
					METASTASIS OF CANCER
					CELLS
Vietnam	1-2011-01744	01/12/2010			COMPOUNDS,
Victiaiii	1-2011-01/44	01/12/2010			COMPOSITIONS, AND
					METHODS FOR
					PREVENTING
					METASTASIS OF CANCER
					CELLS
United States	61/390,899	10/07/2010			COMPOSITIONS AND
Office States	01/390,099	10/07/2010			METHODS FOR
					TREATING OCULAR
					EDEMA AND
					NEOVASCULAZATION
					AND RELATED DISEASES
United States	13/253,397	10/05/2011			COMPOSITIONS AND
Office States	13/233,377	10/03/2011			METHODS FOR
					TREATING OCULAR
					EDEMA AND
					NEOVASCULAZATION
					AND RELATED DISEASES
United States	14/300,385	01/10/2014			COMPOSITIONS AND
Office States	14/300,363	01/10/2014			METHODS FOR
					TREATING OCULAR
					EDEMA,
					NEOVASCULARIZATION
					AND RELATED DISEASES
United States	15/462,326	03/17/2017		1	COMPOSITIONS AND
omicu states	13/402,320	03/1//201/			METHODS FOR
					TREATING OCULAR
					EDEMA,
				1	NEOVASCULARIZATION
					AND RELATED DISEASES
United States	16/513,103	07/16/2019			COMPOSITIONS AND
Omicu States	10/313,103	07/10/2019			METHODS FOR
					TREATING OCULAR
			<u> </u>	<u> </u>	EDEMA,

		I	I	I	NEONA COLHA DIZATIONI
					NEOVASCULARIZATION
					AND RELATED DISEASES
United States	17/352,698	06/21/2021			COMPOSITIONS AND
					METHODS FOR
					TREATING OCULAR
					EDEMA,
					NEOVASCULARIZATION
					AND RELATED DISEASES
United States	15/796,293	10/27/2017			PHOSPHATASE
	, in the second				INHIBITORS FOR
					TREATING OCULAR
					DISEASES
WO	PCT/US2011/0548	10/05/2011			COMPOSITIONS AND
','	73	10,00,2011			METHODS FOR
	, ,				TREATING OCULAR
					EDEMA AND
					NEOVASCULAZATION
					AND RELATED DISEASES
Europe	11831498.8	10/05/2011	2624916	01/17/201	COMPOSITIONS AND
Lutope	11031470.0	10/03/2011	2024910	8	METHODS FOR
				0	TREATING OCULAR
					EDEMA,
					NEOVASCULAZATION
	110214000	10/07/2011	2624016	01/17/201	AND RELATED DISEASES
Germany	11831498.8	10/05/2011	2624916	01/17/201	COMPOSITIONS AND
				8	METHODS FOR
					TREATING OCULAR
					EDEMA,
					NEOVASCULAZATION
					AND RELATED DISEASES
France	11831498.8	10/05/2011	2624916	01/17/201	COMPOSITIONS AND
				8	METHODS FOR
					TREATING OCULAR
					EDEMA,
					NEOVASCULAZATION
					AND RELATED DISEASES
United	11831498.8	10/05/2011	2624916	01/17/201	COMPOSITIONS AND
Kingdom				8	METHODS FOR
					TREATING OCULAR
					EDEMA,
					NEOVASCULAZATION
					AND RELATED DISEASES
Ireland	11831498.8	10/05/2011	2624916	01/17/201	COMPOSITIONS AND
				8	METHODS FOR
					TREATING OCULAR
					EDEMA,
					NEOVASCULAZATION
					AND RELATED DISEASES
Australia	2011312203	10/05/2011	201131220	11/10/201	COMPOSITIONS AND
Australia	2011312203	10/03/2011	3	6	METHODS FOR
			3		TREATING OCULAR
					EDEMA,
					NEOVASCULARIZATION
					AND RELATED DISEASES

Australia	2016204410	10/05/2011	201620441	01/17/201	COMPOSITIONS AND
Austrana	2016204410	10/05/2011	201620441	01/17/201	COMPOSITIONS AND
			0	9	METHODS FOR
					TREATING OCULAR
					EDEMA,
					NEOVASCULARIZATION
					AND RELATED DISEASES
Brazil	BR112013008452-	10/05/2011			COMPOSITIONS AND
	9				METHODS FOR
					TREATING OCULAR
					EDEMA,
					NEOVASCULAZATION
					AND RELATED DISEASES
Canada	2,818,215	10/05/2011	2,818,215	07/21/201	COMPOSITIONS AND
	, ,			5	METHODS FOR
					TREATING OCULAR
					EDEMA,
					NEOVASCULAZATION
					AND RELATED DISEASES
Canada	2,890,554	10/05/2011			COMPOSITIONS AND
Canada	2,000,001	10,00,2011			METHODS FOR
					TREATING OCULAR
					EDEMA,
					NEOVASCULAZATION
					AND RELATED DISEASES
China	201180059165.0	10/05/2011			COMPOSITIONS AND
Cillia	201100039103.0	10/03/2011			METHODS FOR
					TREATING OCULAR
					EDEMA,
					NEOVASCULAZATION
CI.	201/(1000/(050.0	10/05/2011			AND RELATED DISEASES
China	201610996050.9	10/05/2011			COMPOSITIONS AND
					METHODS FOR
					TREATING OCULAR
					EDEMA,
					NEOVASCULAZATION
					AND RELATED DISEASES
Hong Kong	14101185.7	10/05/2011			COMPOSITIONS AND
					METHODS FOR
					TREATING OCULAR
					EDEMA,
					NEOVASCULAZATION
					AND RELATED DISEASES
Israel	229786	10/05/2011	229786	05/29/201	COMPOSITIONS AND
				7	METHODS FOR
					TREATING OCULAR
					EDEMA,
					NEOVASCULAZATION
					AND RELATED DISEASES
Japan	2013-532904	10/05/2011			COMPOSITIONS AND
					METHODS FOR
					TREATING OCULAR
					EDEMA,
					NEOVASCULAZATION
					AND RELATED DISEASES
			I.	i	

ONS AND S FOR
OCULAR
A,
A, AZATION
DISEASES
ONS AND
S FOR
OCULAR
A,
AZATION
DISEASES
ONS AND
S FOR
DCULAR
A,
AZATION
DISEASES
ONS AND
S FOR
OCULAR
Α,
AZATION
DISEASES
ONS AND
S FOR
OCULAR
Α,
RIZATION
DISEASES
ONS AND
S FOR
OCULAR
A,
AZATION
DISEASES
ONS AND
S FOR
OCULAR
A,
AZATION
DISEASES
ONS AND
S FOR
OCULAR
A,
AZATION
DISEASES
ONS AND
S FOR
OCULAR
ı
A,
A, AZATION

New Zealand	705624	10/05/2011	705624	01/05/201	COMPOSITIONS AND
14cw Zealand	703024	10/03/2011	703024	7	METHODS FOR
				,	TREATING OCULAR
					EDEMA,
					NEOVASCULAZATION
					AND RELATED DISEASES
Philippines	1-2013-500577	10/05/2011	1-2013-	06/14/201	COMPOSITIONS AND
			500577	9	METHODS FOR
					TREATING OCULAR
					EDEMA,
					NEOVASCULAZATION
					AND RELATED DISEASES
Russian	2013120064	10/05/2011	2600794		COMPOSITIONS AND
Federation				10/04/201	METHODS FOR
				6	TREATING OCULAR
					EDEMA,
					NEOVASCULAZATION
		10/07/2011			AND RELATED DISEASES
Singapore	2013023809	10/05/2011	189177	11/16/201	COMPOSITIONS AND
				5	METHODS FOR
					TREATING OCULAR
					EDEMA AND
					NEOVASCULAZATION
South Africa	2013/03005	10/05/2011	2013/0300	01/29/201	AND RELATED DISEASES COMPOSITIONS AND
South Africa	2013/03003	10/03/2011	5	4	METHODS FOR
			,	+	TREATING OCULAR
					EDEMA,
					NEOVASCULAZATION
					AND RELATED DISEASES
Thailand	1301001776	10/05/2011			COMPOSITIONS AND
					METHODS FOR
					TREATING OCULAR
					EDEMA AND
					NEOVASCULAZATION
					AND RELATED DISEASES
United States	61/792,679	03/15/2013			COMPOSITIONS AND
					METHODS FOR
					TREATING OCULAR
		<u> </u>			DISEASES
United States	61/792,868	03/15/2013			COMPOSITIONS AND
					METHODS FOR
					TREATING OCULAR
TT to 1 Co. c	(1/000 040	00/05/0010			DISEASES
United States	61/882,048	09/25/2013			COMPOSITIONS AND
					METHODS FOR
					TREATING OCULAR DISEASES
United States	61/882,056	09/25/2013			COMPOSITIONS AND
Omicu States	01/002,030	09/23/2013			METHODS FOR
					TREATING OCULAR
					DISEASES
United States	61/934,570	01/31/2014			COMPOSITIONS AND
	011757,570	01/31/2014			METHODS FOR
		1	l	l	

					TREATING OCULAR DISEASES
United States	13/999,670	03/14/2014	9,440,963	09/13/201	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United States	14/214,413	03/14/2014			COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES
United States	15/098,955	04/14/2016			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United States	15/099,161	04/14/2016			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United States	15/355,910	11/18/2016	10,220,048	03/05/201	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United States	15/443,622	02/27/2017			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United States	15/958,346	04/20/2018			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United States	15/958,355	04/20/2018			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United States	15/958,358	04/20/2018			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United States	15/969,109	05/02/2018			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United States	16/257,287	01/25/2019			COMPOSITIONS AND METHODS FOR

					TREATING OCULAR DISEASES
United States	16/559,006	09/03/2019			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United States	16/888,247	05/29/2020			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United States	17/155,463	01/22/2021			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
WO	PCT/US2014/0297 23	03/14/2014			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Europe	14762974.5	03/14/2014	2967066	10/23/201	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Europe	19174479.6	03/14/2014			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Germany	14762974.5	03/14/2014	602014055 602.7	10/23/201	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
France	14762974.5	03/14/2014	2967066	10/23/201 9	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United Kingdom	1411935,8	03/14/2014	GB251656 1	03/09/201 6	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United Kingdom	1520656.8	03/14/2014	2540638	01/17/201	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES

	T	T	1		
United	1709419.4	03/14/2014	2549865	01/17/201	COMPOSITIONS,
Kingdom				8	FORMULATIONS AND
					METHODS FOR
					TREATING OCULAR
					DISEASES
United	14762974.5	14-Mar-	2967066	10/23/201	COMPOSITIONS,
Kingdom		2014		9	FORMULATIONS AND
Timguom		2011			METHODS FOR
					TREATING OCULAR
					DISEASES
Casia	14762974.5	14 Mon	2967066	10/23/201	COMPOSITIONS.
Spain	14/629/4.3	14-Mar-	2967066		
		2014		9	FORMULATIONS AND
					METHODS FOR
					TREATING OCULAR
					DISEASES
Ireland	14762974.5	03/14/2014	2967066	10/23/201	COMPOSITIONS,
				9	FORMULATIONS AND
					METHODS FOR
					TREATING OCULAR
					DISEASES
Italy	14762974.5	03/14/2014	2967066	10/23/201	COMPOSITIONS,
luity	11702571.5	05/11/2011	2907000	9	FORMULATIONS AND
					METHODS FOR
					TREATING OCULAR
					DISEASES
A t 1 : -	2014233363	03/14/2014	201422226	10/12/201	
Australia	2014233303	03/14/2014	201423336	10/12/201	COMPOSITIONS,
			3	7	FORMULATIONS AND
					METHODS FOR
					TREATING OCULAR
					DISEASES
Australia	2017235953	03/14/2014			COMPOSITIONS,
					FORMULATIONS AND
					METHODS FOR
					TREATING OCULAR
					DISEASES
Brazil	1120150237533	03/14/2014			COMPOSITIONS.
					FORMULATIONS AND
					METHODS FOR
					TREATING OCULAR
					DISEASES
Canada	2,903,871	03/14/2014			COMPOSITIONS.
Canaga	2,903,0/1	03/14/2014			FORMULATIONS AND
					METHODS FOR
					TREATING OCULAR
	201400070777	00/11/2021	10500-101	0.4/1.5/2.5	DISEASES
China	201480028572.9	03/14/2014	105307498	04/16/201	COMPOSITIONS,
				9	FORMULATIONS AND
					METHODS FOR
					TREATING OCULAR
					DISEASES
China	201910221542.4	03/14/2014			COMPOSITIONS,
					FORMULATIONS AND
					METHODS FOR
		I	1		

					TREATING OCULAR DISEASES
Israel	240786	03/14/2014	240786	11/01/201 9	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
India	9436/DELNP/2015	03/14/2014			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Indonesia	P00201506598	03/14/2014			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Israel	267997	03/14/2014			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Japan	2016-503207	03/14/2014	6,572,201	08/16/201 9	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Japan	2019-147238	03/14/2014	6865254	04/07/202	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Japan	2021-64106	03/14/2014			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Korea	10-2015-7029411	03/14/2014			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Malaysia	PI 2015002288	03/14/2014	MY- 171945-A	11/08/201 9	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Malaysia	PI2019000040	03/14/2014			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES

Mexico	MX/a/2015/011131	03/14/2014	371382	01/28/202	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR
Mexico	MX/a/2020/001060	03/14/2014			DISEASES COMPOSITIONS, FORMULATIONS AND METHODS FOR
New Zealand	712694	03/14/2014			TREATING OCULAR DISEASES COMPOSITIONS.
New Zealand	/12074	03/14/2014			FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
New Zealand	750667	03/14/2014			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Philippines	1-2015-502153	03/14/2014	1-2015- 502153	9	COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Philippines	1-2019-502018	03/14/2014			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Singapore	11201507131W	03/14/2014			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
South Africa	2015/07387	03/14/2014			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
South Africa	2020/00522	03/14/2014			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
Thailand	1501005287	03/14/2014			COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES
United States	61/953,680	03/14/2014			HPTP-BETA INHIBITORS

United States	14/657,276	03/14/2014	9,994,560	06/12/201	HPTP-BETA INHIBITORS
United States	14/03/,2/0	03/14/2014	9,994,300	8	HP1P-DE1A INHIDITORS
				8	
United States	15/972,863	05/07/2018	10,858,354	12/08/202	HPTP-BETA INHIBITORS
Cinica States	13/7/2,003	03/07/2010	10,030,331	0	
United States	17/062,098	10/02/2020			HPTP-BETA INHIBITORS
WO	PCT/US2015/0204	03/13/2015			HPTP-BETA INHIBITORS
	25				
Europe	15760687.2	03/13/2015			HPTP-BETA INHIBITORS
China	201580026210.0	03/13/2015			HPTP-BETA INHIBITORS
Japan	2016-556997	3/13/2015	6483148	02/22/201	HPTP-BETA INHIBITORS
				9	
Japan	2018-246712	3/13/2015	6661744	02/14/202	HPTP-BETA INHIBITORS
				0	
	2010 55000	04/16/2010			LIDER DETA DILIBITORS
Japan	2019-77696	04/16/2019			HPTP-BETA INHIBITORS
United States	62/034,695	08/07/2014			COMBINATION OF
Office States	02/034,093	08/07/2014			IMMUNOTHERAPIES
					WITH ACTIVATORS OF
					TIE-2
United States	14/819,871	08/06/2015	9,539,245	01/10/201	COMBINATION OF
	•			7	IMMUNOTHERAPIES
					WITH ACTIVATORS OF
					TIE-2
United States	15/365,186	11/30/2016			COMBINATION OF
					IMMUNOTHERAPIES
					WITH ACTIVATORS OF
WO	PCT/US2015/0440	08/06/2015			TIE-2 COMBINATION OF
"	30	00/00/2013			IMMUNOTHERAPIES
	50				WITH ACTIVATORS OF
					TIE-2
United States	62/019,002	06/30/2014			METHODS OF
					TREATING SEXUAL
					DISORDERS WITH
					ACTIVATORS OF TIE-2
United States	62/190,871	07/10/2015			METHODS OF
	7				TREATING SEXUAL
					DISORDERS WITH
					ACTIVATORS OF TIE-2
		İ	l	<u> </u>	TOTT THE ONLY OF THE Z

United States	62/361,703	07/13/2016			METHODS OF
Office States	02/301,703	07/13/2010			
					TREATING SEXUAL
					DISORDERS WITH
					ACTIVATORS OF TIE-2
United States	62/222,481	09/23/2015			METHODS OF TREATING
					INTRAOCULAR
					PRESSURE WITH
					ACTIVATORS OF TIE-2
United States	15/273,068	09/22/2016	10,952,992	03/23/202	METHODS OF TREATING
				1	INTRAOCULAR
					PRESSURE WITH
					ACTIVATORS OF TIE-2
United States	17/150,430	01/15/2021			METHODS OF TREATING
					INTRAOCULAR
					PRESSURE WITH
					ACTIVATORS OF TIE-2
WO	PCT/US2016/0531	09/22/2016			METHODS OF TREATING
	07				INTRAOCULAR
					PRESSURE WITH
					ACTIVATORS OF TIE-2
Europe	16849594.3	09/22/2016			METHODS OF TREATING
_					INTRAOCULAR
					PRESSURE WITH
					ACTIVATORS OF TIE-2
Australia	2016326510	09/22/2016			METHODS OF TREATING
					INTRAOCULAR
					PRESSURE WITH
					ACTIVATORS OF TIE-2
Brazil	1120180054992	09/22/2016			METHODS OF TREATING
					INTRAOCULAR
					PRESSURE WITH
					ACTIVATORS OF TIE-2
Canada	2,998,673	09/22/2016			METHODS OF TREATING
	_,,				INTRAOCULAR
					PRESSURE WITH
					ACTIVATORS OF TIE-2
China	201680068508.2	09/22/2016			METHODS OF TREATING
					INTRAOCULAR
					PRESSURE WITH
					ACTIVATORS OF TIE-2
India	201817014284	09/22/2016			METHODS OF TREATING
	20101/01/201	33,22,2010			INTRAOCULAR
					PRESSURE WITH
					ACTIVATORS OF TIE-2
Indonesia	P00201802937	09/22/2016			METHODS OF TREATING
	100201002737	37,22,2010			INTRAOCULAR
					PRESSURE WITH
					ACTIVATORS OF TIE-2
Israel	258150	09/22/2016			METHODS OF TREATING
ISIACI	250150	07,22,2010			INTRAOCULAR
					PRESSURE WITH
					ACTIVATORS OF TIE-2
Japan	2018-534502	09/22/2016			METHODS OF TREATING
Japan	2010-JJ#JUZ	07/22/2010			INTRAOCULAR
					ITTICACCULAR
		l			

Resident ACTIVATORS OF TIE-2				PRESSURE WITH
North				
Republic of				ACTIVATORS OF TIE-2
Republic of	Vorce	10 2019 7010229	00/22/2016	METHODS OF THE ATING
Malaysia		10-2016-7010226	09/22/2010	
Malaysia	Republic of			
Malaysia P12018000423 09/22/2016 METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 Mexico MX/a/2018/003542 09/22/2016 METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 New Zealand 740730 09/22/2016 METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 Philippines 1-2018-500658 09/22/2016 METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 Singapore 11201802402U 09/22/2016 METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 Singapore 10201912000W 09/22/2016 METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 South Africa 2018/01795 09/22/2016 METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 United States 62/635,102 09/22/2016 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS United States 62/790,646 01/10/2019 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS United States 16/284,349 02/25/2019 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS United States 17/130,687 12/22/2020 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS <td></td> <td></td> <td></td> <td></td>				
Mexico	Molovicio	DI2018000422	00/22/2016	
Mexico	Iviaiay Sia	112016000423	09/22/2010	
Mexico MX/a/2018/003542 09/22/2016 METHODS OF TIE-2 METHODS OF TIE-3 New Zealand 740730 09/22/2016 METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS METHODS OF TREATING DIABETIC NE				
Mexico				
New Zealand	Mexico	MX/2/2018/003542	09/22/2016	
PRESSURE WITH ACTIVATORS OF TIE-2	Wickied	1012010/003342	07/22/2010	
New Zealand				
New Zealand				
Philippines	New Zealand	740730	09/22/2016	
PRESSURE WITH ACTIVATORS OF TIE-2	14cw Zealand	740730	07/22/2010	
Philippines				
Philippines				
INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2	Philippines	1-2018-500658	09/22/2016	
PRESSURE WITH ACTIVATORS OF TIE-2	Timppines	1-2010-300030	07/22/2010	
Singapore 11201802402U 09/22/2016 METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2				
Singapore 11201802402U 09/22/2016 METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2				
INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2	Singapore	1120180240211	09/22/2016	
PRESSURE WITH ACTIVATORS OF TIE-2	Singapore	112010024020	07/22/2010	
Singapore 10201912000W 09/22/2016 METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS METHOD				
Singapore 10201912000W 09/22/2016 METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS METHODS OF TREAT				
INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2	Singapore	10201912000W	09/22/2016	
PRESSURE WITH ACTIVATORS OF TIE-2	Singapore	10201712000 **	03/22/2010	
South Africa 2018/01795 09/22/2016 METHODS OF TIE-2				
South Africa 2018/01795 09/22/2016 METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2				
United States	South Africa	2018/01795	09/22/2016	
United States 62/635,102 02/26/2018 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS United States 62/790,646 01/10/2019 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS United States 16/284,349 02/25/2019 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS United States 17/130,687 12/22/2020 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS United States 02/790,646 01/10/2019 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS WO PCT/US2019/0193 666 02/25/2019 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS MO PCT/US2019/0193 666 02/25/2019 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS			****-	
ACTIVATORS OF TIE-2 United States				
United States 62/635,102 02/26/2018 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS United States 62/790,646 01/10/2019 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS United States 16/284,349 02/25/2019 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS United States 17/130,687 12/22/2020 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS WO PCT/US2019/0193 66 02/25/2019 METHODS OF TREATING DIABETIC NEPHROPATHY USING				
United States 62/790,646 01/10/2019 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS United States 16/284,349 02/25/2019 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS United States 17/130,687 12/22/2020 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS United States 17/130,687 12/22/2020 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS WO PCT/US2019/0193 66 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS METHODS OF TREATING DIABETIC NEPHROPATHY USING METHODS OF TREATING DIABETIC NEPHROPATHY USING	United States	62/635,102	02/26/2018	
NEPHROPATHY USING HPTPB INHIBITORS				
HPTPB INHIBITORS				
United States 62/790,646 01/10/2019 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS United States 16/284,349 02/25/2019 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS United States 17/130,687 12/22/2020 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS WO PCT/US2019/0193 666 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS METHODS OF TREATING DIABETIC NEPHROPATHY USING DIABETIC NEPHROPATHY USING				
United States 16/284,349 02/25/2019 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS United States 17/130,687 12/22/2020 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS WO PCT/US2019/0193 66 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS METHODS OF TREATING DIABETIC NEPHROPATHY USING DIABETIC NEPHROPATHY USING DIABETIC NEPHROPATHY USING	United States	62/790,646	01/10/2019	
United States 16/284,349 02/25/2019 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS United States 17/130,687 12/22/2020 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS WO PCT/US2019/0193 66 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS METHODS OF TREATING DIABETIC NEPHROPATHY USING DIABETIC NEPHROPATHY USING		,		DIABETIC
United States 16/284,349 02/25/2019 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS United States 17/130,687 12/22/2020 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS WO PCT/US2019/0193 66 02/25/2019 METHODS OF TREATING DIABETIC NEPHROPATHY USING DIABETIC NEPHROPATHY USING				NEPHROPATHY USING
United States 17/130,687 12/22/2020 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS WO PCT/US2019/0193 666 02/25/2019 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS METHODS OF TREATING DIABETIC NEPHROPATHY USING				HPTPB INHIBITORS
United States 17/130,687 12/22/2020 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS WO PCT/US2019/0193 666 02/25/2019 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS METHODS OF TREATING DIABETIC NEPHROPATHY USING	United States	16/284,349	02/25/2019	METHODS OF TREATING
United States 17/130,687 12/22/2020 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS WO PCT/US2019/0193 666 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS METHODS OF TREATING DIABETIC NEPHROPATHY USING		ĺ		
United States 17/130,687 12/22/2020 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS WO PCT/US2019/0193 66 METHODS OF TREATING DIABETIC NEPHROPATHY USING DIABETIC NEPHROPATHY USING				NEPHROPATHY USING
WO PCT/US2019/0193 02/25/2019 METHODS OF TREATING 66 DIABETIC NEPHROPATHY USING HPTPB INHIBITORS METHODS OF TREATING DIABETIC NEPHROPATHY USING				HPTPB INHIBITORS
WO PCT/US2019/0193 02/25/2019 METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS METHODS OF TREATING DIABETIC NEPHROPATHY USING	United States	17/130,687	12/22/2020	METHODS OF TREATING
WO PCT/US2019/0193 02/25/2019 METHODS OF TREATING DIABETIC NEPHROPATHY USING				DIABETIC
WO PCT/US2019/0193 02/25/2019 METHODS OF TREATING DIABETIC NEPHROPATHY USING				NEPHROPATHY USING
66 DIABETIC NEPHROPATHY USING			<u> </u>	HPTPB INHIBITORS
NEPHROPATHY USING	WO	PCT/US2019/0193	02/25/2019	METHODS OF TREATING
		66		DIABETIC
HPTPB INHIBITORS				NEPHROPATHY USING
				HPTPB INHIBITORS

Europe	19756688.8	02/25/2019	METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS
Japan	2020-567452	02/25/2019	METHODS OF TREATING DIABETIC NEPHROPATHY USING HPTPB INHIBITORS
United States	62/835,626	04/18/2019	METHODS OF TREATING HYPERTENSION WITH ACTIVATORS OF TIE-2
United States	62/840,655	04/30/2019	METHODS OF TREATING PULMONARY HYPERTENSION USING TIE-2 ACTIVATORS
United States	16/850,613	04/16/2020	METHODS OF TREATING HYPERTENSION WITH ACTIVATORS OF TIE-2
WO	PCT/US2020/0285 77	04/16/2020	METHODS OF TREATING HYPERTENSION WITH ACTIVATORS OF TIE-2
United States	62/865,653	06/24/2019	FORMULATIONS OF TIE-2 ACTIVATORS AND METHODS OF USE THEREOF
United States	63/009,083	04/13/2020	FORMULATIONS OF TIE-2 ACTIVATORS AND METHODS OF USE THEREOF
United States	16/908,996	06/23/2020	FORMULATIONS OF TIE-2 ACTIVATORS AND METHODS OF USE THEREOF
United Kingdom	2009592.3	06/23/2020	FORMULATIONS OF TIE-2 ACTIVATORS AND METHODS OF USE THEREOF
United States	62/927,233	10/29/2019	SMALL MOLECULE ACTIVATORS OF TIE-2
United States	17/082,612	10/28/2020	SMALL MOLECULE ACTIVATORS OF TIE-2
WO	PCT/US2020/0576 41	10/28/2020	SMALL MOLECULE ACTIVATORS OF TIE-2
United States	62/840,068	04/29/2019	TIE-2 ACTIVATORS TARGETING SCHLEMM'S CANAL
United States	16/860,347	04/28/2020	TIE-2 ACTIVATORS TARGETING SCHLEMM'S CANAL

WO	PCT/US2020/0302	04/28/2020	TIE-2 ACTIVATORS
	24		TARGETING THE
			SCHLEMM'S CANAL
United States	62/958,348	01/08/2020	COMBINATIONS OF TIE-2
			ACTIVATORS AND
			PROSTAGLANDINS AND
			USES THEREOF
United States	63/089,144	10/08/2020	COMBINATIONS OF TIE-2
			ACTIVATORS AND
			PROSTAGLANDINS AND
			USES THEREOF
United States	17/143,394	01/07/2021	COMBINATIONS OF TIE-2
			ACTIVATORS AND
			PROSTAGLANDINS AND
			USES THEREOF
WO	PCT/US2021/0124	01/07/2021	COMBINATIONS OF TIE-2
	07		ACTIVATORS AND
			PROSTAGLANDINS AND
			USES THEREOF
United States	63/127,412	12/18/2020	DOSAGE FORMS OF TIE-2
			ACTIVATORS
United States	63/127,411	12/18/2020	METHODS FOR
Office States	05/12/,411	12/16/2020	MANUFACTURE OF
			SMALL ACTIVATORS OF
			TIE-2
United States	63/028,317	05/21/2020	METHODS OF TREATING
			ACUTE RESPIRATORY
			DISTRESS SYNDROME
			WITH ACTIVATORS OF
			TIE-2
WO	PCT/US2021/0334	05/20/2021	METHODS OF TREATING
	95		ACUTE RESPIRATORY
			DISTRESS SYNDROME
			WITH ACTIVATORS OF
			TIE-2

ATTACHMENT B

Country	Application No.	Filing Date	Patent No.	Patent Date	Title
United States	60/790,506	04/07/200			ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA)
United States	60/798,896	05/09/200			ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA)
United States	11/784,094	04/05/200 7	7,973,142	07/05/201	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA)
United States	15/430,100	02/10/201 7	9,926,367	03/27/201	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
United States	15/894,442	02/12/201			ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
United States	16/696,212	11/26/201 9			ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
United States	16/784,970	02/07/202			ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE beta (HPTPbeta) AND USES THEREOF
United States	13/115,180	05/25/201	8,524,235	09/03/201	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA)
United States	13/958,990	08/05/201			ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA)

ACTIVE/111122520.9

PATENT REEL: 057448 FRAME: 0084

TIVO	DOTE/ID0005/05100	04/07/200	I	<u> </u>	A JEHO OD IEG ETT A E DE TO
WO	PCT/IB2007/05123	04/05/200			ANTIBODIES THAT BIND
	9	7			HUMAN PROTEIN
					TYROSINE
					PHOSPHATASE BETA
E-man	07725409.2	04/05/200			(HPTPBETA)
Europe	07735408.2	04/05/200			ANTIBODIES THAT BIND HUMAN PROTEIN
		/			TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
					THEREOF
Europe	11155518.1	04/05/200	2371865	07/12/201	ANTIBODIES THAT BIND
		7		7	HUMAN PROTEIN
					TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
					THEREOF
Europe	17169315.3	04/05/201	3252079	07/29/202	ANTIBODIES THAT BIND
		7		0	HUMAN PROTEIN
					TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
	0 = 0 /= 0 0 0				THEREOF
United Arab	978/2008	04/05/200			ANTIBODIES THAT BIND
Emirates		7			HUMAN PROTEIN
					TYROSINE
					PHOSPHATASE BETA (HPTPBETA) AND USES
					THEREOF
Austria	11155518.1	04/05/200	2371865	07/12/201	ANTIBODIES THAT BIND
7 tustriu	11133310.1	7	2371003	7	HUMAN PROTEIN
				·	TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
					THEREOF
Australia	2007237096	04/05/200	200723709	12/20/201	ANTIBODIES THAT BIND
		7	6	2	HUMAN PROTEIN
					TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
					THEREOF
Belgium	11155518.1	04/05/200	2371865	07/12/201	ANTIBODIES THAT BIND
		7		7	HUMAN PROTEIN
					TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
Brazil	PI 0710645-9	04/05/200			THEREOF ANTIBODIES THAT BIND
DIAZII	F10/10043-9	7			HUMAN PROTEIN
					TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
					THEREOF
	l	l		ı	

Canada	2,648,284	04/05/200	2,648,284	08/16/201	ANTIBODIES THAT BIND
		7		6	HUMAN PROTEIN
					TYROSINE PHOSPHATASE BETA
					(HPTPBETA) AND USES
					THEREOF
Switzerland	11155518.1	04/05/200	2371865	07/12/201	ANTIBODIES THAT BIND
		7		7	HUMAN PROTEIN
					TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES THEREOF
China	200780011778.0	04/05/200	ZL	08/31/201	ANTIBODIES THAT BIND
		7	200780011	6	HUMAN PROTEIN
			778.0		TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
C1 :	201/10/1000	0.4.40.5.49.00			THEREOF
China	201610648805.6	04/05/200			ANTIBODIES THAT BIND HUMAN PROTEIN
					TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
					THEREOF
Colombia	08-105786	04/05/200	4311	08/24/201	ANTIBODIES THAT BIND
		7		2	HUMAN PROTEIN
					TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES THEREOF
Germany	602007051642.0	04/05/200	2371865	07/12/201	ANTIBODIES THAT BIND
o o mana	00200100101.2.0	7	2511555	7	HUMAN PROTEIN
					TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
					THEREOF
Germany	602007060503.2	04/05/201	3252079	07/29/202	ANTIBODIES THAT BIND
		7		0	HUMAN PROTEIN TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
					THEREOF
Denmark	11155518.1	04/05/200	2371865	07/12/201	ANTIBODIES THAT BIND
		7		7	HUMAN PROTEIN
					TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES THEREOF
Egypt	1612/2008	04/05/200			ANTIBODIES THAT BIND
_5, pt	1012/2000	7			HUMAN PROTEIN
					TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
					THEREOF

	<u></u>		ı		
Spain	11155518.1	04/05/200	2371865	07/12/201 7	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
					THEREOF
Cnoin	17169315.3	04/05/201	3252079	07/29/202	ANTIBODIES THAT BIND
Spain	1/109313.3	7	3232079	07/29/202	HUMAN PROTEIN
		'			TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
					THEREOF
Finland	11155518.1	04/05/200	2371865	07/12/201	ANTIBODIES THAT BIND
Timanu	11133316,1	7	23/1803	7	HUMAN PROTEIN
		'		/	TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
					THEREOF
France	11155518.1	04/05/200	2371865	07/12/201	ANTIBODIES THAT BIND
Tance	11133316.1	7	2371003	7	HUMAN PROTEIN
		'		,	TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
					THEREOF
France	17169315.3	04/05/201	3252079	07/29/202	ANTIBODIES THAT BIND
Tance	17107313.3	7	3232019	0	HUMAN PROTEIN
					TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
					THEREOF
United	11155518.1	04/05/200	2371865	07/12/201	ANTIBODIES THAT BIND
Kingdom		7		7	HUMAN PROTEIN
					TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
					THEREOF
United	17169315.3	04/05/201	3252079	07/29/202	ANTIBODIES THAT BIND
Kingdom		7		0	HUMAN PROTEIN
					TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
					THEREOF
Indonesia	W00200803006	04/05/200	IDP000051	07/10/201	ANTIBODIES THAT BIND
		7	812	8	HUMAN PROTEIN
					TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
					THEREOF
Ireland	11155518.1	04/05/200	2371865	07/12/201	ANTIBODIES THAT BIND
		7		7	HUMAN PROTEIN
					TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
					THEREOF

50 10/01/201 ANTIBODIES THAT BIND
5 HUMAN PROTEIN
TYROSINE
PHOSPHATASE BETA
(HPTPBETA) AND USES
THEREOF
20 05/01/201 ANTIBODIES THAT BIND
9 HUMAN PROTEIN
TYROSINE
PHOSPHATASE BETA
(HPTPBETA) AND USES
THEREOF ANTIBODIES THAT BIND
HUMAN PROTEIN
TYROSINE
PHOSPHATASE BETA
(HPTPBETA) AND USES
THEREOF
47 01/29/201 ANTIBODIES THAT BIND
6 HUMAN PROTEIN
TYROSINE
PHOSPHATASE BETA
(HPTPBETA) AND USES
THEREOF
365 07/12/201 ANTIBODIES THAT BIND
7 HUMAN PROTEIN
TYROSINE
PHOSPHATASE BETA
(HPTPBETA) AND USES
THEREOF 079 07/29/202 ANTIBODIES THAT BIND
0 HUMAN PROTEIN
TYROSINE
PHOSPHATASE BETA
(HPTPBETA) AND USES
THEREOF
898 12/28/201 ANTIBODIES THAT BIND
2 HUMAN PROTEIN
TYROSINE
PHOSPHATASE BETA
(HPTPBETA) AND USES
THEREOF
ANTIBODIES THAT BIND
HUMAN PROTEIN
TYROSINE
PHOSPHATASE BETA
(HPTPBETA) AND USES THEREOF
ANTIBODIES THAT BIND
HUMAN PROTEIN
TYROSINE
PHOSPHATASE BETA
(HPTPBETA) AND USES
THEREOF

	2016 20664	0.4.10.7.10.00		00/0=/001	A TEMPORATE STATE OF THE STATE
Japan	2016-226664	04/05/200	6395791	09/07/201	ANTIBODIES THAT BIND
		7		8	HUMAN PROTEIN
					TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
					THEREOF
Japan	2017-131042	04/05/200			ANTIBODIES THAT BIND
		7			HUMAN PROTEIN
					TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
					THEREOF
Japan	2018-246735	04/05/200			ANTIBODIES THAT BIND
Jupun	2010 210733	7			HUMAN PROTEIN
		·			TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
					THEREOF
Korea	10.2000.7026044	04/05/200			
Korea	10-2008-7026944	04/05/200			ANTIBODIES THAT BIND
		7			HUMAN PROTEIN
					TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
					THEREOF
Korea	10-2011-7024995	04/05/200			ANTIBODIES THAT BIND
		7			HUMAN PROTEIN
					TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
					THEREOF
Korea	10-2013-7022106	04/05/200	1482483	01/07/201	ANTIBODIES THAT BIND
		7		5	HUMAN PROTEIN
					TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
					THEREOF
Morocco	PV/31325	04/05/200	30353	04/01/200	ANTIBODIES THAT BIND
		7		9	HUMAN PROTEIN
				-	TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
					THEREOF
Mexico	MX/a/2008/012991	04/05/200	295062	01/23/201	ANTIBODIES THAT BIND
MICAICO	112342000012771	7	273002	2	HUMAN PROTEIN
		'			TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
					· ` ′
Malania	DI 20000002070	04/05/200	MSZ	01/15/201	THEREOF
Malaysia	PI 20080003870	04/05/200	MY-	01/15/201	ANTIBODIES THAT BIND
		7	150400-A	4	HUMAN PROTEIN
					TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
					THEREOF

NT 41 1 1	11155510.1	04/05/200	2271075	07/10/001	ANTERODIEC THAT DIVID
Netherlands	11155518.1	04/05/200	2371865	07/12/201	ANTIBODIES THAT BIND
		7		7	HUMAN PROTEIN
					TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
					THEREOF
New Zealand	571300	04/05/200	571300	04/02/201	ANTIBODIES THAT BIND
		7		2	HUMAN PROTEIN
					TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
					THEREOF
Philippines	1-2008-502246	04/05/200			ANTIBODIES THAT BIND
		7			HUMAN PROTEIN
					TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
					THEREOF
Poland	11155518.1	04/05/200	2371865	07/12/201	ANTIBODIES THAT BIND
		7		7	HUMAN PROTEIN
					TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
					THEREOF
Portugal	11155518.1	04/05/200	2371865	07/12/201	ANTIBODIES THAT BIND
1 ortugui	11133310.1	7	2371003	7	HUMAN PROTEIN
		'		, ,	TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
					THEREOF
Russia	2008138399	04/05/200	2473565	01/27/201	ANTIBODIES THAT BIND
Russia	2000130377	7	2473303	3	HUMAN PROTEIN
]	TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
					THEREOF
Russia	2011141686	04/05/200	2494108	09/27/201	ANTIBODIES THAT BIND
Russia	2011141060	7	2494106	3	
		/		3	HUMAN PROTEIN TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
G 1	11155510.1	0.4/0.7/0.00	2271067	07/10/001	THEREOF
Sweden	11155518.1	04/05/200	2371865	07/12/201	ANTIBODIES THAT BIND
		7		7	HUMAN PROTEIN
					TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
		1			THEREOF
Singapore	200806979-1	04/05/200			ANTIBODIES THAT BIND
		7			HUMAN PROTEIN
					TYROSINE
					PHOSPHATASE BETA
					(HPTPBETA) AND USES
					THEREOF

Singapore	201102498-1	04/05/200 7	170842	04/09/201	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
San Marino	P-200800060	04/05/200 7	SM-AP- 200800060		ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Turkey	11155518.1	04/05/200 7	2371865	07/12/201 7	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
Vietnam	1-2008-02466	04/05/200 7	14457	08/17/201	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
South Africa	2008/07978	04/05/200 7	2008/0797	08/26/200	ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES THEREOF
United States	61/546,708	10/13/201 1			TREATMENT OF OCULAR DISEASE
United States	13/652,154	10/15/201	8,999,325	04/07/201 5	TREATMENT OF OCULAR DISEASE
United States	14/627,463	02/20/201			TREATMENT OF OCULAR DISEASES
United States	15/463,340	03/20/201 7	10,329,357	06/25/201 9	TREATMENT OF OCULAR DISEASES
United States	16/395,972	04/26/201 9			TREATMENT OF OCULAR DISEASES
United States	16/751,824	01/24/202			TREATMENT OF OCULAR DISEASES
WO	PCT/US2012/0602 63	10/15/201			TREATMENT OF OCULAR DISEASE
Europe	12840725.1	10/15/201 2	2766044	12/11/201 9	TREATMENT OF OCULAR DISEASE

Europe	18202143.6	10/15/201			TREATMENT OF OCULAR DISEASE
Australia	2012323849	10/15/201	201232384	08/03/201 7	TREATMENT OF OCULAR DISEASE
Brazil	112014008759-8	10/15/201			TREATMENT OF OCULAR DISEASE
Canada	2,850,824	10/15/201			TREATMENT OF OCULAR DISEASE
China	201280054482.8	10/15/201			TREATMENT OF OCULAR DISEASE
China	201710084072.2	10/15/201			TREATMENT OF OCULAR DISEASE
Germany	12840725.1	10/15/201	602012066 453.3	12/11/201 9	TREATMENT OF OCULAR DISEASE
Spain	12840725.1	10/15/201 2	2766044	12/11/201 9	TREATMENT OF OCULAR DISEASE
France	12840725.1	10/15/201	2766044	12/11/201 9	TREATMENT OF OCULAR DISEASE
United Kingdom	12840725.1	10/15/201	2766044	12/11/201 9	TREATMENT OF OCULAR DISEASE
Hong Kong	15101784.1	10/15/201			TREATMENT OF OCULAR DISEASE
Hong Kong	15101828.9	10/15/201			TREATMENT OF OCULAR DISEASE
Ireland	12840725.1	10/15/201	2766044	12/11/201 9	TREATMENT OF OCULAR DISEASE
Italy	12840725.1	10/15/201	2766044	12/11/201 9	TREATMENT OF OCULAR DISEASE
Japan	2014-535978	10/15/201			TREATMENT OF OCULAR DISEASE
Japan	2016-178592	10/15/201	6259503	12/15/201 7	TREATMENT OF OCULAR DISEASE
Japan	2016-178593	10/15/201			TREATMENT OF OCULAR DISEASE

Japan	2018-103592	10/15/201			TREATMENT OF OCULAR DISEASE
Japan	2018-103593	10/15/201			TREATMENT OF OCULAR DISEASE
Mexico	MX/a/2014/004449	10/15/201	347226	04/19/201 7	TREATMENT OF OCULAR DISEASE
New Zealand	623275	10/15/201 2	623275	08/30/201 6	TREATMENT OF OCULAR DISEASE
United States	61/546,697	10/13/201			METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
United States	61/546,748	10/13/201			METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
United States	13/652,203	10/15/201			METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
United States	15/438,218	02/21/201 7	10,150,811	12/11/201 8	METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
United States	16/168,060	10/23/201	10,815,300	10/27/202	METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
United States	17/027,034	09/21/202			METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
WO	PCT/US2012/0602 73	10/15/201			METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
Europe	12840220.3	10/15/201			METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
Europe	18201774.9	10/15/201			METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
Australia	2012323856	10/15/201	201232385	09/07/201 7	METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
Brazil	112014008819-5	10/15/201			METHODS FOR TREATING VASCULAR

					LEAK CYAIDDONE AND
					LEAK SYNDROME AND
					CANCER
Canada	2,850,830	10/15/201			METHODS FOR
		2			TREATING VASCULAR
					LEAK SYNDROME AND
					CANCER
China	201280052307.5	10/15/201			METHODS FOR
		2			TREATING VASCULAR
					LEAK SYNDROME AND
					CANCER
China	201910768287.5	10/15/201			METHODS FOR
		2			TREATING VASCULAR
					LEAK SYNDROME AND
					CANCER
Hong Kong	15101641.4	10/15/201			METHODS FOR
		2			TREATING VASCULAR
					LEAK SYNDROME AND
					CANCER
Japan	2014-535979	10/15/201			METHODS FOR
		2			TREATING VASCULAR
					LEAK SYNDROME AND
					CANCER
Japan	2017-130652	10/15/201			METHODS FOR
		2			TREATING VASCULAR
					LEAK SYNDROME AND
					CANCER
Japan	2017-143622	07/25/201			METHODS FOR
		7			TREATING VASCULAR
					LEAK SYNDROME AND
					CANCER
Japan	2019-87483	10/15/201	6706367	05/19/202	METHODS FOR
		2		0	TREATING VASCULAR
					LEAK SYNDROME AND
					CANCER
Japan	2019-115666	10/15/201			METHODS FOR
_		2			TREATING VASCULAR
					LEAK SYNDROME AND
					CANCER
Mexico	MX/a/2014/004448	10/15/201	363351	03/20/201	METHODS FOR
		2		9	TREATING VASCULAR
					LEAK SYNDROME AND
					CANCER
Mexico	MX/a/2019/002983	10/15/201			METHODS FOR
		2			TREATING VASCULAR
		_			LEAK SYNDROME AND
					CANCER
New Zealand	623283	10/15/201	623283	08/30/201	METHODS FOR
		2		6	TREATING VASCULAR
		_			LEAK SYNDROME AND
					CANCER
United States	62/054,752	24-Sep-			VE-PTP EXTRACELLULAR
		2014			DOMAIN ANTIBODIES
					DELIVERED BY A GENE
					THERAPY
		I.	l	1	

United States	14/862,948	09/23/201			VE-PTP EXTRACELLULAR
		5			DOMAIN ANTIBODIES
					DELIVERED BY A GENE
					THERAPY
United States	15/815,097	11/16/201			VE-PTP EXTRACELLULAR
		7			DOMAIN ANTIBODIES
					DELIVERED BY A GENE
					THERAPY
WO	PCT/US2015/0517	09/23/201			VE-PTP EXTRACELLULAR
	19	5			DOMAIN ANTIBODIES
					DELIVERED BY A GENE
					THERAPY
United States	62/364,381	07/20/201			HUMANIZED
		6			MONOCLONAL
					ANTIBODY THAT
					TARGETS VE-PTP
United States	62/377,072	08/19/201			HUMANIZED
		6			MONOCLONAL
					ANTIBODY THAT
					TARGETS VE-PTP
United States	15/654,289	07/19/201	10,253,094	04/09/201	HUMANIZED
		7		9	MONOCLONAL
					ANTIBODY THAT
					TARGETS VE-PTP (HPTP-
					Beta)
United States	16/180,850	11/05/201	10,604,569	03/31/202	HUMANIZED
		8		0	MONOCLONAL
					ANTIBODIES THAT
					TARGET VE-PTP (HPTP-
					Beta)
United States	16/180,854	11/05/201	10,597,452	03/24/202	HUMANIZED
		8		0	MONOCLONAL
					ANTIBODIES THAT
					TARGET VE-PTP (HPTP-
					Beta)
United States	16/775,860	01/29/202			HUMANIZED
		0			MONOCLONAL
					ANTIBODIES THAT
					TARGET VE-PTP (HPTP-
					Beta)
United States	16/851,420	04/17/202			HUMANIZED
		0			MONOCLONAL
					ANTIBODIES THAT
					TARGET VE-PTP (HPTP-
					Beta)
Europe	17831790.5	07/19/201			HUMANIZED
1		7			MONOCLONAL
					ANTIBODY THAT
					TARGETS VE-PTP
WO	PCT/US2017/0428	07/19/201			HUMANIZED
	55	7			MONOCLONAL
					ANTIBODY THAT
					TARGETS VE-PTP
					TARGETS VE-PTP

A . 41 I	2017200501	07/10/201	THEATANTEE
Australia	2017299581	07/19/201	HUMANIZED
		7	MONOCLONAL
			ANTIBODY THAT
			TARGETS VE-PTP
Brazil	1120190012060	07/19/201	HUMANIZED
		7	MONOCLONAL
			ANTIBODY THAT
			TARGETS VE-PTP
Canada	3,030,298	07/19/201	HUMANIZED
	-,,	7	MONOCLONAL
		·	ANTIBODY THAT
			TARGETS VE-PTP
China	201780057896.9	07/19/201	HUMANIZED
	201700057070.7	7	MONOCLONAL
		, , , , , , , , , , , , , , , , , , ,	ANTIBODY THAT
			TARGETS VE-PTP
Indonesia	PID201900449	07/19/201	HUMANIZED
muonesia	P1D201900449	7	MONOCLONAL
		/	
			ANTIBODY THAT
T 1	262026	07/10/201	TARGETS VE-PTP
Israel	263936	07/19/201	HUMANIZED
		7	MONOCLONAL
			ANTIBODY THAT
			TARGETS VE-PTP
India	201817049429	07/19/201	HUMANIZED
		7	MONOCLONAL
			ANTIBODY THAT
			TARGETS VE-PTP
Japan	2019-502696	07/19/201	HUMANIZED
		7	MONOCLONAL
			ANTIBODY THAT
			TARGETS VE-PTP
Japan	2020-120521	07/19/201	HUMANIZED
		7	MONOCLONAL
		·	ANTIBODY THAT
			TARGETS VE-PTP (HPTP-
			β)
Korea	10-2019-7002479	07/19/201	HUMANIZED
Roica	10 2017 7002477	7	MONOCLONAL
		, ,	ANTIBODY THAT
			TARGETS VE-PTP
Mexico	MX/a/2019/000727	07/19/201	HUMANIZED
Mexico	NIA/a/2019/000/2/	1	MONOCLONAL
		7	
			ANTIBODY THAT
7.1	DI2010000120	07/10/201	TARGETS VE-PTP
Malaysia	PI2019000120	07/19/201	HUMANIZED
		7	MONOCLONAL
			ANTIBODY THAT
			TARGETS VE-PTP
New Zealand	749494	07/19/201	HUMANIZED
		7	MONOCLONAL
			ANTIBODY THAT
		<u> </u>	TARGETS VE-PTP

Philippines	1-2019-500145	07/19/201	HUMANIZED
1 mappines	1 2017 300113	7	MONOCLONAL
		/	ANTIBODY THAT
			TARGETS VE-PTP
Singapore	11201900464T	07/19/201	HUMANIZED
		7	MONOCLONAL
			ANTIBODY THAT
			TARGETS VE-PTP
Singapore	10201912556V	07/19/201	HUMANIZED
		7	MONOCLONAL
			ANTIBODY THAT
			TARGETS VE-PTP
South Africa	2019/00368	07/19/201	HUMANIZED
		7	MONOCLONAL
			ANTIBODY THAT
			TARGETS VE-PTP
South Africa	2020/01991	07/19/201	HUMANIZED
		7	MONOCLONAL
			ANTIBODIES THAT
			TARGET VE-PTP (HPTP-ß)

ATTACHMENT C

Country	Application No.	Filing Date	Patent No.	Patent Date	Title
United States	62/735,331	09/24/201			BISPECIFIC ANTIBODIES
		8			THAT TARGET VE-PTP
					(HPTP-B) AND VEGF
United States	62/832,461				MULTISPECIFIC
		04/11/201			ANTIBODIES THAT
		9			TARGET HPTP-B (VE-PTP)
					AND VEGF
United States	16/579,078	09/23/201	10,894,82	01/19/202	MULTISPECIFIC
		9	4	1	ANTIBODIES THAT
					TARGET HPTP-B (VE-PTP)
					AND VEGF
United States	17/117,993				MULTISPECIFIC
		12/10/202			ANTIBODIES THAT
		0			TARGET HPTP-B (VE-PTP)
					AND VEGF
WO	PCT/US2019/0524	09/23/201			MULTISPECIFIC
	05	9			ANTIBODIES THAT
					TARGET HPTP-B (VE-PTP)
					AND VEGF
Europe	19867311.3	09/23/201			MULTISPECIFIC
		9			ANTIBODIES THAT
					TARGET HPTP-B (VE-PTP)
					AND VEGF
China	201980077336.9	09/23/201			MULTISPECIFIC
		9			ANTIBODIES THAT
					TARGET HPTP-B (VE-PTP)
					AND VEGF

ACTIVE/111122520.9

PATENT REEL: 057448 FRAME: 0097

Japan	2021-516373	09/23/201		MULTISPECIFIC
		9		ANTIBODIES THAT
				TARGET HPTP-β (VE-PTP)
				AND VEGF

ACTIVE/111122520.9

RECORDED: 09/09/2021

PATENT REEL: 057448 FRAME: 0098